KR102315879B1 - Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same - Google Patents
Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same Download PDFInfo
- Publication number
- KR102315879B1 KR102315879B1 KR1020210009548A KR20210009548A KR102315879B1 KR 102315879 B1 KR102315879 B1 KR 102315879B1 KR 1020210009548 A KR1020210009548 A KR 1020210009548A KR 20210009548 A KR20210009548 A KR 20210009548A KR 102315879 B1 KR102315879 B1 KR 102315879B1
- Authority
- KR
- South Korea
- Prior art keywords
- strain
- composition
- food
- present application
- cjcc02
- Prior art date
Links
- 235000000471 Rhizopus oligosporus Nutrition 0.000 title claims abstract description 81
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 78
- 241000235547 Rhizopus microsporus var. oligosporus Species 0.000 title claims abstract 6
- 239000012871 anti-fungal composition Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 103
- 235000013305 food Nutrition 0.000 claims abstract description 52
- 241000894006 Bacteria Species 0.000 claims abstract description 45
- 241000233866 Fungi Species 0.000 claims abstract description 32
- 230000000813 microbial effect Effects 0.000 claims abstract description 27
- 239000003814 drug Substances 0.000 claims abstract description 23
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 21
- 230000036541 health Effects 0.000 claims abstract description 21
- 235000013376 functional food Nutrition 0.000 claims abstract description 20
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 239000012141 concentrate Substances 0.000 claims abstract description 12
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 206010016952 Food poisoning Diseases 0.000 claims description 29
- 208000019331 Foodborne disease Diseases 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 241000228212 Aspergillus Species 0.000 claims description 15
- 241000193755 Bacillus cereus Species 0.000 claims description 15
- 235000013548 tempeh Nutrition 0.000 claims description 14
- 241000228245 Aspergillus niger Species 0.000 claims description 12
- 241000272525 Anas platyrhynchos Species 0.000 claims description 7
- 240000006439 Aspergillus oryzae Species 0.000 claims description 4
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 4
- 235000015067 sauces Nutrition 0.000 claims description 4
- 208000004998 Abdominal Pain Diseases 0.000 claims description 2
- 206010000060 Abdominal distension Diseases 0.000 claims description 2
- 206010010774 Constipation Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 244000205939 Rhizopus oligosporus Species 0.000 description 75
- 239000002609 medium Substances 0.000 description 29
- 239000000047 product Substances 0.000 description 23
- 238000000034 method Methods 0.000 description 21
- 238000012258 culturing Methods 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 235000021107 fermented food Nutrition 0.000 description 11
- 244000005700 microbiome Species 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 244000068988 Glycine max Species 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 10
- 206010028520 Mycotoxicosis Diseases 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 241000209140 Triticum Species 0.000 description 7
- 235000021307 Triticum Nutrition 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 108010062877 Bacteriocins Proteins 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 235000013312 flour Nutrition 0.000 description 6
- -1 for example Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 108020004463 18S ribosomal RNA Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000001965 potato dextrose agar Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 241000251468 Actinopterygii Species 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 101150061715 abp1 gene Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000000369 enteropathogenic effect Effects 0.000 description 4
- 235000019688 fish Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000013379 molasses Nutrition 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000006150 trypticase soy agar Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 3
- 108010022172 Chitinases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003674 animal food additive Substances 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 101150071577 chi2 gene Proteins 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 239000002577 cryoprotective agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910010272 inorganic material Inorganic materials 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 235000013555 soy sauce Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000012286 Chitinases Human genes 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000235527 Rhizopus Species 0.000 description 2
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 2
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 240000000359 Triticum dicoccon Species 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000015099 wheat brans Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 239000004129 EU approved improving agent Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000235029 Zygosaccharomyces bailii Species 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000021405 artificial diet Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000020420 bandung Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000001477 organic nitrogen group Chemical group 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001522 polyglycol ester Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010027322 single cell proteins Proteins 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
- A01N63/30—Microbial fungi; Substances produced thereby or obtained therefrom
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
- A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3571—Microorganisms; Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/845—Rhizopus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Agronomy & Crop Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Medical Informatics (AREA)
- Dentistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Oncology (AREA)
- Birds (AREA)
Abstract
Description
본 출원은 기탁번호 KCCM12893P로 기탁된 리조푸스 올리고스포러스 CJCC02-20 (Rhizopus oligosporus CJCC02-20) 균주; 상기 균주, 균주의 포자, 균주의 배양물, 그의 농축물 및 그의 건조물로 이루어지는 군으로부터 선택되는 어느 하나 이상을 유효성분으로 포함하는, 항균 조성물; 상기 항균 조성물을 포함하는 식품 조성물; 사료 조성물; 의약외품 조성물; 건강기능식품 조성물; 또는 상기 항균 조성물을 포함하는, 진균, 세균 또는 이들의 조합으로 인한 미생물 감염 질환의 예방 또는 치료용 약학 조성물에 관한 것이다. The present application is a Rhizopus oligosporus CJCC02-20 (Rhizopus oligosporus CJCC02-20) strain deposited with accession number KCCM12893P; An antibacterial composition comprising, as an active ingredient, any one or more selected from the group consisting of the strain, the spore of the strain, the culture of the strain, its concentrate and its dried product; a food composition comprising the antimicrobial composition; feed composition; quasi-drug composition; health functional food composition; Or it relates to a pharmaceutical composition for the prevention or treatment of microbial infections caused by fungi, bacteria, or a combination thereof, including the antibacterial composition.
전통 방식으로 제조된 발효식품은 원료 보관, 제조 및 유통 과정에서 항시 진균류와 식중독 균에 취약하다. 진균류 및 식중독 유발 세균은 열처리 후에도 살아남아 식품의 변패 및 부패 혹은 식중독을 유발시키는 것으로 알려져 있다. Fermented food manufactured in a traditional way is always vulnerable to fungi and food poisoning bacteria during the storage, manufacturing and distribution of raw materials. Fungi and food poisoning-causing bacteria are known to survive heat treatment and cause spoilage and spoilage of food or food poisoning.
변패 및 식중독균 증식을 방지하여, 상기 식품의 품질을 오랫동안 유지하기 위해 항균물질에 관한 연구가 많이 진행되어 왔다. 항균물질 중에서 특히 안전성과 경제성이 우수한 천연 보존제에 대한 연구의 필요성이 증대되고 있는 실정이다.In order to prevent spoilage and proliferation of food poisoning bacteria, and to maintain the quality of the food for a long time, a lot of research on antibacterial substances has been conducted. Among antibacterial substances, the need for research on natural preservatives with excellent safety and economical efficiency is increasing.
대표적인 천연보존제로 박테리오신은 미생물이 생산하는 천연 항균성 단백질 또는 단백질계의 물질을 의미한다. 박테이오신은 단백질이기에 인체에서 분해가 가능하여 안전성이 입증된 물질이다. 이는 기존 항생제의 2차 대사산물로 인체에 부작용을 발생시키는 것과 대조되어 박테리오신에 대한 연구의 필요성이 증대되고 있는 실정이다. 상기 박테리오신과 관련하여, 최근까지 유산균 유래 박테리오신에 관한 연구가 주를 이루고 있다. 유산균 유래 박테리오신은 GRAS 등급으로 안전성이 입증됐다는 장점이 있으나, 항균 활성 범위가 그람 양성균로 특이적이기 때문에 널리 활용되지 못하고 있다. As a representative natural preservative, bacteriocin refers to a natural antibacterial protein or protein-based material produced by microorganisms. Bacteosin is a protein, so it can be decomposed in the human body, and thus its safety has been proven. In contrast to the secondary metabolites of existing antibiotics that cause side effects in the human body, the need for research on bacteriocins is increasing. With respect to the bacteriocin, studies on lactic acid bacteria-derived bacteriocins have been predominant until recently. Lactobacillus-derived bacteriocin has the advantage of being proven safe with a GRAS grade, but it is not widely used because the antibacterial activity range is specific to Gram-positive bacteria.
리조푸스 올리고스포러스의 항균성과 관련하여 리조푸스 올리고스포러스 배양액으로부터 생성된 항균 물질 Antibiotic peptide (ABP) 과 Linoleic acid 등은 그람 양성균인 Straphyloccoccus 속 및 Bascillus 속을 제어하는 것으로 알려져 있다(Kusumah et al., 2020; Nowak and Steinkraus, 1988; Roubos-van den Hil et al., 2010; Wang et al., 1969). 그러나 그람 양성인 특정 미생물에 대한 항균 활성만이 보고되고 있을 뿐, 변패 또는 식중독을 유발하는 다양한 균주에 대해 효과에 대해서는 보고된 바가 없다. 나아가, 리조푸스 올리고스포러스는 발효 음식에서 유용한 세균이므로, 상기 박테리오신을 발효식품에 적용할 경우 변패 유발 진균류 및 식중독 세균류에도 특정한 활성을 보인다고 보기 어려워서 발효 식품을 산업화하여 제조 및 유통하기에 어려운 문제가 있다. With respect to the antimicrobial properties of Rhizopus oligosporus , antibiotic peptide (ABP) and Linoleic acid, which are antibacterial substances produced from the culture medium of Rhizopus oligosporus , are known to control the gram-positive genus Straphyloccoccus and Bascillus (Kusumah et al. , 2020; Nowak and Steinkraus, 1988; Roubos-van den Hil et al., 2010; Wang et al., 1969). However, only antibacterial activity against specific microorganisms that are gram-positive has been reported, and there is no report on the effect on various strains causing decomposition or food poisoning. Furthermore, since Rhizopus oligosporus is a useful bacterium in fermented food, when the bacteriocin is applied to fermented food, it is difficult to see that it exhibits specific activity in rot-inducing fungi and food poisoning bacteria. have.
이에 본 발명자들은, 인체에 무해하면서 다양한 진균류 및 세균류를 억제하는 방법을 개발하고자 예의 연구 노력한 결과, 템페(tempe)로부터 신규 분리한 리조푸스 올리고스포러스 CJCC02-20가 진균에 대한 항균 활성을 가질 뿐만 아니라, 식중독 세균 등 식품의 주요 위해 미생물만을 특이적으로 억제하는 항균 활성이 있음을 확인하여 본 출원을 완성하였다. Accordingly, the present inventors made intensive research efforts to develop a method for inhibiting various fungi and bacteria while harmless to the human body. As a result, Rhizopus oligosporus CJCC02-20 newly isolated from tempe has antibacterial activity against fungi as well as Rather, the present application was completed by confirming that there is an antibacterial activity that specifically inhibits only major harmful microorganisms in food such as food poisoning bacteria.
본 출원은 기탁번호 KCCM12893P로 기탁된 리조푸스 올리고스포러스 CJCC02-20 (Rhizopus oligosporus CJCC02-20) 균주; 상기 균주, 균주의 포자, 균주의 배양물, 그의 농축물 및 그의 건조물로 이루어지는 군으로부터 선택되는 어느 하나 이상을 유효성분으로 포함하는, 항균 조성물; 상기 항균 조성물을 포함하는 식품 조성물; 사료 조성물; 의약외품 조성물; 건강기능식품 조성물 또는 상기 항균 조성물을 포함하는, 진균, 세균 또는 이들의 조합으로 인한 미생물 감염 질환의 예방 또는 치료용 약학 조성물에 관한 것이다. The present application is a Rhizopus oligosporus CJCC02-20 (Rhizopus oligosporus CJCC02-20) strain deposited with accession number KCCM12893P; An antibacterial composition comprising, as an active ingredient, any one or more selected from the group consisting of the strain, the spore of the strain, the culture of the strain, its concentrate and its dried product; a food composition comprising the antimicrobial composition; feed composition; quasi-drug composition; It relates to a pharmaceutical composition for preventing or treating microbial infections caused by fungi, bacteria, or a combination thereof, including a health functional food composition or the antibacterial composition.
본 출원의 하나의 목적은 기탁번호 KCCM12893P로 기탁된 리조푸스 올리고스포러스 CJCC02-20 (Rhizopus oligosporus CJCC02-20) 균주를 제공하는 것이다. One object of the present application is to provide a Rhizopus oligosporus CJCC02-20 (Rhizopus oligosporus CJCC02-20) strain deposited with accession number KCCM12893P.
본 출원의 다른 하나의 목적은 상기 리조푸스 올리고스포러스 CJCC02-20 균주, 균주의 포자, 균주의 배양물, 그의 농축물 및 그의 건조물로 이루어지는 군으로부터 선택되는 어느 하나 이상을 유효성분으로 포함하는, 항균 조성물을 제공하는 것이다. Another object of the present application is to include, as an active ingredient, any one or more selected from the group consisting of the Rhizopus oligosporus CJCC02-20 strain, the spore of the strain, the culture of the strain, its concentrate, and its dried product, To provide an antibacterial composition.
본 출원의 또 다른 하나의 목적은 상기 항균 조성물을 포함하는 식품 조성물을 제공하는 것이다. Another object of the present application is to provide a food composition comprising the antibacterial composition.
본 출원의 또 다른 하나의 목적은 상기 항균 조성물을 포함하는 사료 조성물을 제공하는 것이다. Another object of the present application is to provide a feed composition comprising the antibacterial composition.
본 출원의 또 다른 하나의 목적은 상기 항균 조성물을 포함하는 의약외품 조성물을 제공하는 것이다. Another object of the present application is to provide a quasi-drug composition comprising the antibacterial composition.
본 출원의 또 다른 하나의 목적은 상기 항균 조성물을 포함하는 건강기능식품 조성물을 제공하는 것이다. Another object of the present application is to provide a health functional food composition comprising the antibacterial composition.
본 출원의 또 다른 하나의 목적은 상기 항균 조성물을 포함하는, 진균, 세균 또는 이들의 조합으로 인한 미생물 감염 질환의 예방 또는 치료용 약학 조성물을 제공하는 것이다. Another object of the present application is to provide a pharmaceutical composition for preventing or treating microbial infections caused by fungi, bacteria, or a combination thereof, including the antibacterial composition.
상기 목적을 달성하기 위하여, 본 출원의 하나의 양태는 기탁번호 KCCM12893P로 기탁된 리조푸스 올리고스포러스 CJCC02-20 (Rhizopus oligosporus CJCC02-20) 균주를 제공한다. In order to achieve the above object, one aspect of the present application provides a Rhizopus oligosporus CJCC02-20 strain deposited with accession number KCCM12893P.
본 발명자들은 발효식품의 품질저하 및 오염을 유발시키는 진균 및 식중독 유발 세균에 뛰어난 항균 활성을 가지는 리조푸스 올리고스포러스에 속하는 신규한 균주를 하기와 같이 규명하였다. The present inventors have identified a novel strain belonging to Rhizopus oligosporus having excellent antibacterial activity against fungi and food poisoning-causing bacteria that cause deterioration and contamination of fermented food as follows.
재래식 템페로부터 다종의 리조푸스 올리고스포러스를 분리하여 곰팡이, 효모 등 진균류 및 식중독 세균류에 대해 검정한 결과 항균 활성이 우수한 균주 리조푸스 올리고스포러스를 선별하고, 선별된 균주를 동정하기 위하여 유전자 염기서열 분석을 수행하였다. 상기 선별된 균주의 18S rRNA 염기서열은 서열번호 1로 기재하였으며, ABP(antibiotic peptide) 유전자 서열은 서열번호 2에 기재하였고, Chitinase(Chi2) 유전자 서열은 서열번호 3에 기재하였다. 상기 유전자 분석을 기초하여 상기 균주를 리조푸스 올리고스포러스 균주로 동정하고, 리조푸스 올리고스포러스 CJCC02-20로 명명하였으며, 부다페스트 조약 하의 국제기탁기관인 한국미생물보존센터(KCCM)에 2020년 12월 09일자로 기탁하고 수탁번호 KCCM12893P를 부여 받았다. As a result of isolating various types of Rhizopus oligosporus from conventional tempeh and testing for fungi, yeast, etc. and food poisoning bacteria, a strain with excellent antibacterial activity was selected, and gene sequencing to identify the selected strain. Analysis was performed. The 18S rRNA base sequence of the selected strain is described in SEQ ID NO: 1, the antibiotic peptide (ABP) gene sequence is described in SEQ ID NO: 2, and the Chitinase (Chi2) gene sequence is described in SEQ ID NO: 3. Based on the above genetic analysis, the strain was identified as a Rhizopus oligosporus strain, and was named Rhizopus oligosporus CJCC02-20, and was sent to the Korea Microorganism Conservation Center (KCCM), an international depository under the Budapest Treaty, on December 09, 2020. It was deposited on the date and was given an accession number KCCM12893P.
본 출원의 일 구체예에 의하면, 상기 신규 분리된 리조푸스 올리고스포러스 CJCC02-20는 진균 및 식중독 유발 세균에 대한 항균활성이 우수하여, 다양한 진균류 및 식중독 유발세균에 동시에 작용할 수 있는 항균활성을 나타낸다(실시예 3). According to one embodiment of the present application, the newly isolated Rhizopus oligosporus CJCC02-20 has excellent antibacterial activity against fungi and food poisoning-inducing bacteria, and exhibits antibacterial activity that can act simultaneously on various fungi and food poisoning-causing bacteria. (Example 3).
상기 진균 및 세균은 아스퍼질러스(Aspergillus) 속, 바실러스(Bacillus) 속, 에스케리아(Escherichia) 속일 수 있으나, 이에 제한 되는 것은 아니다. The fungi and bacteria may be of the genus Aspergillus , the genus Bacillus , and the genus Escherichia , but is not limited thereto.
본 출원의 일 구체예로서, 상기 리조푸스 올리고스포러스 CJCC02-20는 진균인 아스퍼질러스 오리재(Aspergillus oryzae), 아스퍼질러스 나이거(Aspergillus niger) 또는 이들의 조합에 대하여 항균활성을 가지는 것일 수 있으나, 상기 진균의 종류에 한정되는 것은 아니다. As an embodiment of the present application, the Rhizopus oligosporus CJCC02-20 is a fungus that has antibacterial activity against Aspergillus oryzae , Aspergillus niger , or a combination thereof. However, it is not limited to the type of the fungus.
본 출원의 일 구체예로서, 상기 리조푸스 올리고스포러스 CJCC02-20는 바실러스 세레우스(Bacillus cereus), 대장균(Escherichia coli) 또는 이들의 조합에 대하여 항균활성을 가지는 것일 수 있으나, 상기 세균의 종류에 한정되는 것은 아니다.As an embodiment of the present application, the Rhizopus oligosporus CJCC02-20 may have antibacterial activity against Bacillus cereus , Escherichia coli , or a combination thereof, but depending on the type of bacteria It is not limited.
본 출원의 일 구체예로서, 상기 리조푸스 올리고스포러스 CJCC02-20는 아스퍼질러스 오리재, 아스퍼질러스 나이거 또는 대장균에 특이적 항균활성을 가지는 것일 수 있으나, 이에 한정되는 것은 아니다. As an embodiment of the present application, the Rhizopus oligosporus CJCC02-20 may have specific antibacterial activity against Aspergillus duck material, Aspergillus niger or E. coli, but is not limited thereto.
상기 아스퍼질러스 오리재, 아스퍼질러스 나이거는 발효식품의 품질 저하 및 오염 유발 균주로 알려져 있으며, 바실러스 세레우스 및 대장균은 식중독의 유발 균으로 알려져 있는 바, 이에 뛰어난 항균활성을 가지는 리조푸스 올리고스포러스 CJCC02-20는 다양한 용도로 사용될 수 있다. The Aspergillus duck material and Aspergillus niger are known as strains that cause deterioration and contamination of fermented food, and Bacillus cereus and E. coli are known as food poisoning causative bacteria, and Rhizopus oligospo having excellent antibacterial activity. Russ CJCC02-20 can be used for various purposes.
상기 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 신규 분리된 리조푸스 올리고스포러스 CJCC02-20 균주, 상기 균주의 포자, 상기 균주의 배양물, 그의 농축물, 그의 추출물, 및 그의 건조물로 이루어지는 군으로부터 선택되는 어느 하나 이상; 및 담체를 포함하는 조성물을 제공한다. As another aspect for achieving the above object, the present application relates to the novel isolated Rhizopus oligosporus CJCC02-20 strain, the spores of the strain, the culture of the strain, its concentrate, its extract, and its dried product. Any one or more selected from the group consisting of; and a carrier.
이때, 상기 담체는 자연적 또는 비자연적으로 발생하는(non-naturally occurring) 담체일 수 있다.In this case, the carrier may be a naturally or non-naturally occurring carrier.
본 출원의 일 구체예로, 상기 건조물은 동결건조물일 수 있다. In one embodiment of the present application, the dried product may be a freeze-dried product.
또한 상기 조성물은 동결보호제를 추가로 포함할 수 있다. 예를 들어, 글리세롤, 트레할로스, 말토덱스트린, 탈지분유 및 전분으로 이루어진 군으로부터 선택되는 하나 이상의 동결보호제를 추가로 포함할 수 있다. 본 출원의 동결보호제는 본 출원의 조성물 총 중량에 대하여 0.01 중량% 내지 20 중량%, 0.01 중량% 내지 10 중량% 포함될 수 있고, 구체적으로 본 출원의 글리세롤은 5 중량% 내지 20 중량%, 본 출원의 트레할로스는 2 중량% 내지 10 중량%, 본 출원의 말토덱스트린은 2 중량% 내지 10 중량%, 본 출원의 탈지분유는 0.5 중량% 내지 2 중량%, 본 출원의 전분은 0.1 중량% 내지 1 중량%로 본 출원의 조성물에 포함될 수 있다.In addition, the composition may further comprise a cryoprotectant. For example, one or more cryoprotectants selected from the group consisting of glycerol, trehalose, maltodextrin, powdered skim milk and starch may be further included. The cryoprotectant of the present application may be included in 0.01 wt% to 20 wt%, 0.01 wt% to 10 wt%, based on the total weight of the composition of the present application, specifically, the glycerol of the present application is 5 wt% to 20 wt%, the present application of trehalose is 2 wt% to 10 wt%, maltodextrin of the present application is 2 wt% to 10 wt%, skim milk powder of the present application is 0.5 wt% to 2 wt%, starch of the present application is 0.1 wt% to 1 wt% % may be included in the composition of the present application.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 신규 분리된 리조푸스 올리고스포러스 CJCC02-20 균주, 상기 균주의 포자, 상기 균주의 배양물, 그의 농축물, 그의 추출물, 및 그의 건조물로 이루어지는 군으로부터 선택되는 어느 하나 이상을 유효성분으로 포함하는 항균 조성물을 제공한다.As another aspect for achieving the above object, the present application relates to the novel isolated Rhizopus oligosporus CJCC02-20 strain, the spores of the strain, the culture of the strain, its concentrate, its extract, and its dried product It provides an antibacterial composition comprising any one or more selected from the group consisting of as an active ingredient.
이때, 균주의 상태는 액상상태 또는 건조상태일 수 있으나 이에 제한되는 것은 아니다.At this time, the state of the strain may be a liquid state or a dry state, but is not limited thereto.
상기 항균 조성물은 진균, 세균 또는 이들의 조합에 대한 항균활성을 가지는 것일 수 있으며, 구체적으로, 아스퍼질러스 오리재, 아스퍼질러스 나이거 또는 대장균에 특이적 항균활성을 가지는 것일 수 있으며, 바실러스 세레우스에 증진된 항균활성능을 가지는 것일 수 있으나, 이에 한정되는 것은 아니다. The antimicrobial composition may have antibacterial activity against fungi, bacteria, or a combination thereof, and specifically, may have specific antibacterial activity against Aspergillus duck material, Aspergillus niger or E. coli, and Bacillus cerebellum. It may have an enhanced antibacterial activity in the mouse, but is not limited thereto.
본 출원에서 용어, "포자"는 세균 등의 번식 세포를 말하며, 본 출원의 목적상 상기 포자는 리조푸스 올리고스포러스 CJCC02-20의 번식 세포를 의미한다.As used herein, the term “spore” refers to a propagation cell such as bacteria, and for the purpose of the present application, the spore refers to a propagation cell of Rhizopus oligosporus CJCC02-20.
본 출원에서 상기 리조푸스 올리고스포러스 CJCC02-20의 포자는 진균 및 식중독 세균에 대한 항균 활성을 나타내어 항균 활성이 있는 식품, 사료, 의약품, 의약외품, 건강기능식품에 포함되어 사용될 수 있다.In the present application, the spores of the Rhizopus oligosporus CJCC02-20 exhibit antibacterial activity against fungi and food poisoning bacteria, and thus can be used in foods, feeds, pharmaceuticals, quasi-drugs, and health functional foods having antibacterial activity.
본 출원에서 용어, "배양물"은 상기 균주를 배양한 다음 수득한 산물을 의미하며, 균체를 포함한 배양 원액일 수 있으며, 또한 배양 균주, 배양 상등액을 제거하거나 농축한 균체일 수 있다. 상기 배양물의 조성은 통상의 리조푸스 올리고스포러스 배양에 필요한 성분뿐 아니라, 리조푸스 올리고스포러스의 생장에 상승적으로 작용하는 성분을 추가적으로 포함할 수 있으며, 이에 따른 조성은 당업계의 통상의 기술을 가진 자에 의하여 용이하게 선택될 수 있다. As used herein, the term "culture" refers to a product obtained after culturing the strain, and may be a culture stock solution including cells, or may be cells obtained by removing or concentrating cultured strains and culture supernatant. The composition of the culture may additionally include not only components necessary for culturing Rhizopus oligosporus, but also components that act synergistically on the growth of Rhizopus oligosporus, and the composition according to the conventional technique in the art It can be easily selected by those who have it.
본 출원에서 용어, "농축물"은 상기 배양물을 농축한 것을 의미한다.As used herein, the term "concentrate" refers to the concentration of the culture.
본 출원에서 용어, "추출물"은 상기 배양물 또는 그의 농축물로부터 추출한 것을 의미하며, 본 출원의 진균류 및 세균에 특이적 항균 효과를 나타낼 수 있는 추출물인 한, 이에 제한되지는 않고, 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 또는 이들 조정제물 또는 정제물, 이를 분획한 분획물을 모두 포함할 수 있다.As used herein, the term "extract" refers to an extract from the culture or its concentrate, and is not limited thereto, as long as it is an extract capable of exhibiting a specific antibacterial effect on fungi and bacteria of the present application, but is not limited thereto. of the diluted or concentrated solution, the dried product obtained by drying the extract, or these crude products or purified products, and all fractions obtained by fractionation thereof.
본 출원에서 용어, "건조물"은 상기 배양물, 그의 농축물, 그의 추출물, 및 그의 분획물을 건조한 것을 의미한다. 건조방법은 통풍건조, 자연건조, 분무건조 및 동결건조가 가능하지만, 이에 제한되는 것은 아니다.As used herein, the term “dried product” means drying the culture, its concentrate, its extract, and its fraction. The drying method may include, but is not limited to, ventilation drying, natural drying, spray drying and freeze drying.
본 출원의 신규 분리한 리조푸스 올리고스포러스 CJCC02-20는 통상적인 리조푸스 올리고스포러스 균주의 배양방법을 통해 배양할 수 있으나 이에 한정되는 것은 아니다. 배지로는 천연배지 또는 합성배지를 사용할 수 있다. 배지의 탄소원으로는 예를 들어, 글루코오스, 수크로오스, 덱스트린, 글리세롤, 녹말 등이 사용될 수 있고, 질소원으로는 펩톤, 육류 추출물, 효모 추출물, 건조된 효모, 대두, 암모늄염, 나이트레이트 및 기타 유기 또는 무기 질소 함유 화합물이 사용될 수 있으나, 이러한 성분에 한정되는 것은 아니다. 배지에 포함되는 무기염으로는 마그네슘, 망간, 칼슘, 철, 인 등이 사용될 수 있으나, 이들에 한정되는 것은 아니다. 상기 탄소원, 질소원 및 무기염의 성분 이외에 아미노산, 비타민, 핵산 및 그와 관련된 화합물들이 배지에 첨가될 수 있다.The newly isolated Rhizopus oligosporus CJCC02-20 of the present application may be cultured through a conventional culturing method of the Rhizopus oligosporus strain, but is not limited thereto. As the medium, a natural medium or a synthetic medium may be used. As a carbon source of the medium, for example, glucose, sucrose, dextrin, glycerol, starch, etc. may be used, and as a nitrogen source, peptone, meat extract, yeast extract, dried yeast, soybean, ammonium salt, nitrate and other organic or inorganic Nitrogen containing compounds may be used, but are not limited to these components. As the inorganic salt contained in the medium, magnesium, manganese, calcium, iron, phosphorus, etc. may be used, but is not limited thereto. In addition to the components of the carbon source, nitrogen source and inorganic salt, amino acids, vitamins, nucleic acids and related compounds may be added to the medium.
상기 항균 조성물은 리조푸스 올리고스포러스 CJCC02-20를 배양하는 과정에서 생성되는 기타 부산물을 함께 포함할 수 있다.The antibacterial composition may include other by-products generated in the process of culturing Rhizopus oligosporus CJCC02-20 together.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 항균조성물을 포함하는 식품 조성물을 제공한다. As another aspect for achieving the above object, the present application provides a food composition comprising the antimicrobial composition.
상기 식품의 종류는 특별히 제한되지 아니하며, 통상적인 의미에서의 식품을 모두 포함할 수 있다. 상기 물질을 첨가할 수 있는 식품의 비제한적인 예로는 장류, 젓갈류를 포함하는 발효식품, 소스류, 육류, 소시지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등을 들 수 있다. 상기 조성물을 식품 첨가물로 사용할 경우, 상기 조성물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다.The type of the food is not particularly limited, and may include all foods in a conventional sense. Non-limiting examples of foods to which the above substances can be added include soy sauce, fermented foods including salted fish, sauces, meat, sausage, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream Dairy products including dairy products, various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes are included. When the composition is used as a food additive, the composition may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method.
구체적으로, 상기 식품 조성물은 발효식품 일 수 있으며, 구체적으로 장류, 젓갈류 일 수 있으며, 보다 구체적으로 템페일 수 있으나 이에 제한되는 것은 아니다. Specifically, the food composition may be a fermented food, specifically soy sauce, salted fish, and more specifically tempe, but is not limited thereto.
또한, 상기 식품 조성물은 템페를 포함하는 소스류일 수 있으나, 이에 제한 되는 것은 아니다. In addition, the food composition may be a sauce containing tempeh, but is not limited thereto.
상기 식품 조성물은 식품학적으로 허용가능한 담체를 포함할 수 있다. The food composition may include a food pharmaceutically acceptable carrier.
상기 담체의 종류는 특별히 제한되지 않으며 당해 기술 분야에서 통상적으로 사용되는 담체라면 어느 것이든 사용할 수 있다.The type of the carrier is not particularly limited, and any carrier commonly used in the art may be used.
또한, 상기 식품 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예들 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu), 크륨(Cr) 등의 미네랄; 및 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다.In addition, the food composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, and vision. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, pantothenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr); and amino acids such as lysine, tryptophan, cysteine, and valine.
또한, 상기 식품 조성물은 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제, 분산제 등의 식품 첨가물(food additives)을 포함할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별하고 적절한 양으로 사용할 수 있다.In addition, the food composition includes a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), a disinfectant (bleaching powder and high bleaching powder, sodium hypochlorite, etc.), an antioxidant (butylhydroxyanisole (BHA), butyl hydro Loxytoluene (BHT), etc.), coloring agents (tar pigments, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclamate, saccharin, etc.) , sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (flavors), filming agents, gum base agents, foam inhibitors, solvents, improving agents, dispersing agents, etc. of food additives. The additive may be selected according to the type of food and used in an appropriate amount.
특히, 본 발명자들은 본 출원의 신규 분리된 리조푸스 올리고스포러스 CJCC02-20가 장류 발효 곰팡이인 아스퍼질러스 오리재와 식품 오염원인 아스퍼질러스 나이거 및 식중독 세균인 바실러스 세레우스, 장관병원성 세균인 대장균을 동시에 억제할 수 있는 효과가 있음을 확인하였으며(실시예 3, 도 1), 상기 항균 조성물을 발효식품인 템페에 적용한 결과 전통풍미는 구현하면서도 식중독균 방제효과를 유지할 수 있음을 확인하였는 바(실시예 4), 발효식품을 포함한 모든 식품에 직접적으로 사용할 수 있다.In particular, the present inventors found that the newly isolated Rhizopus oligosporus CJCC02-20 of the present application is an enteric fermented mold, Aspergillus duck material, Aspergillus niger, a food contamination source, Bacillus cereus, a food poisoning bacterium, and enteropathogenic bacteria. It was confirmed that there is an effect of simultaneously inhibiting E. coli (Example 3, Fig. 1), and as a result of applying the antibacterial composition to tempeh, a fermented food, it was confirmed that it was possible to maintain the effect of controlling food poisoning bacteria while implementing the traditional flavor ( Example 4), it can be used directly for all foods, including fermented foods.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 항균 조성물을 포함하는, 미생물 감염 질환의 예방 또는 치료용 약학 조성물을 제공한다. As another aspect for achieving the above object, the present application provides a pharmaceutical composition for preventing or treating a microbial infection, including the antibacterial composition.
본 출원에서 사용되는 용어, "예방"이란, 본 출원에 따른 미생물 감염 질환의 예방 또는 치료용 조성물을 개체에 투여하여 미생물 감염 질환의 발병을 억제하거나 지연시키는 모든 행위를 의미할 수 있다.As used herein, the term "prevention" may refer to any action of inhibiting or delaying the onset of a microbial infectious disease by administering the composition for preventing or treating a microbial infection disease according to the present application to an individual.
본 출원에서 사용되는 용어, "치료"란, 본 출원의 상기 조성물을 미생물 감염 질환 발병 의심 개체에 투여하여 미생물 감염 질환의 증세가 호전되도록 하거나 이롭게 되도록 하는 모든 행위를 의미할 수 있다.As used in the present application, the term "treatment" may refer to any act of administering the composition of the present application to a subject suspected of having a microbial infection disease to improve or benefit from symptoms of a microbial infection disease.
본 출원에서 사용되는 용어, "개선"은 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미할 수 있다.As used herein, the term “improvement” may refer to any action that at least reduces a parameter related to a treated condition, for example, the degree of a symptom.
본 출원에서 사용되는 용어, "개체"란, 미생물 감염 질환이 발병되었거나 발병할 가능성이 있는 인간을 포함한 모든 동물을 의미할 수 있다.As used herein, the term "individual" may mean any animal, including humans, that has or is likely to develop a microbial infection disease.
이 때, 미생물 감염 질환은 미생물에 의하여 감염되어 발생하는 질환으로, 바람직하게는 진균 또는 세균에 의해 감염되어 발생하는 질환일 수 있다.In this case, the microbial infection disease is a disease caused by infection by microorganisms, preferably a disease caused by infection by fungi or bacteria.
본 출원의 일 구체예로서, 상기 진균은 아스퍼질러스 오리재, 아스퍼질러스 나이거 또는 이들의 조합일 수 있으나, 이에 제한 되는 것은 아니다. As an embodiment of the present application, the fungus may be Aspergillus duck material, Aspergillus niger, or a combination thereof, but is not limited thereto.
본 출원의 일 구체예로서, 상기 세균은 바실러스 세레우스, 대장균 또는 이들의 조합일 수 있으나, 이에 제한 되는 것은 아니다. In one embodiment of the present application, the bacteria may be Bacillus cereus, E. coli, or a combination thereof, but is not limited thereto.
또한, 본 출원의 일 구체예로서, 상기 미생물 감염 질환은 식중독, 설사, 구토, 장염, 위장관염, 변비, 복통 및 복부팽만으로 이루어지는 군으로부터 선택되는 어느 하나 이상일 수 있으나, 이에 제한되는 것은 아니다. In addition, as an embodiment of the present application, the microbial infection disease may be any one or more selected from the group consisting of food poisoning, diarrhea, vomiting, enteritis, gastroenteritis, constipation, abdominal pain and abdominal distension, but is not limited thereto.
본 출원의 일 실시예에서는 식중독을 유발시킬 수 있는 세균인 바실러스 세레우스에 대하여 증진된 항균활성 및 장관병원성 대장균에 관하여 특이적 항균활성을 확인하였으며, 곰팡이균인 아스퍼질러스 오리재 및 아스퍼질러스 나이거에 대한 특이적 항진균 활성을 확인하였는 바, 본 출원의 항균 조성물은 미생물 감염 질환의 예방 또는 치료용 약학 조성물에 효과적으로 사용될 수 있다. In one embodiment of the present application, the enhanced antibacterial activity against Bacillus cereus, a bacterium that can cause food poisoning, and specific antibacterial activity against enteropathogenic E. coli were confirmed, and the fungi Aspergillus duckjae and Aspergillus As the specific antifungal activity against Niger was confirmed, the antibacterial composition of the present application can be effectively used in a pharmaceutical composition for preventing or treating microbial infectious diseases.
본 출원에 따른 미생물 감염 질환의 예방 또는 치료용 조성물은 약학적으로 허용 가능한 담체를 추가로 포함할 수 있으며, 상기 담체와 함께 제제화되어 식품, 건강기능식품, 의약품, 의약외품, 사료 첨가제 및 음용수 첨가제 등으로 제공될 수 있다. The composition for preventing or treating a microbial infection according to the present application may further include a pharmaceutically acceptable carrier, and is formulated with the carrier to provide food, health functional food, pharmaceuticals, quasi-drugs, feed additives and drinking water additives, etc. can be provided as
본 출원에서 사용되는 용어, "약학적으로 허용 가능한 담체"란 생물체를 자극하지 않으면서, 투여되는 화합물의 생물학적 활성 및 특성을 저해하지 않는 담체 또는 희석제를 의미할 수 있다.As used herein, the term “pharmaceutically acceptable carrier” may refer to a carrier or diluent that does not inhibit the biological activity and properties of an administered compound without irritating the organism.
본 출원에 사용 가능한 상기 담체의 종류는 특별히 제한되지 아니하며 당해 기술 분야에서 통상적으로 사용되고 약학적으로 허용되는 담체라면 어느 것이든 사용할 수 있다. 상기 담체의 비제한적인 예로는, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사 용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 등을 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The type of carrier usable in the present application is not particularly limited, and any carrier commonly used in the art and pharmaceutically acceptable may be used. Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and the like. These may be used alone or in mixture of two or more.
또한, 필요한 경우 항산화제, 완충액 및/또는 정균제 등 다른 통상의 첨가제를 첨가하여 사용할 수 있으며, 희석제, 분산제, 계면 활성제, 결합제, 윤활제 등을 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제 등으로 제제화하여 사용할 수 있다.In addition, if necessary, other conventional additives such as antioxidants, buffers and/or bacteriostats can be added and used, and diluents, dispersants, surfactants, binders, lubricants, etc. It can be used by formulating it into a dosage form, pill, capsule, granule, or tablet.
본 출원에 따른 미생물 감염 질환의 예방 또는 치료용 조성물의 투여 방식은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방식에 따를 수 있다. 상기 투여 방식의 비제한적인 예로, 조성물을 경구 투여 또는 비경구 투여 방식으로 투여할 수 있다. 본 출원의 상기 미생물 감염 질환의 예방, 개선 또는 치료용 조성물은 목적하는 투여 방식에 따라 다양한 제형으로 제작될 수 있다.The method of administering the composition for preventing or treating microbial infection according to the present application is not particularly limited, and may follow a method commonly used in the art. As a non-limiting example of the administration method, the composition may be administered by oral administration or parenteral administration. The composition for preventing, improving, or treating the microbial infectious disease of the present application may be prepared in various formulations according to the desired administration method.
본 출원의 항균물질의 약학적 투여 형태는 이들의 약학적 허용 가능한 염의 형태로도 사용될 수 있고, 또한 단독으로 또는 타 약학적 활성 화합물과 결합뿐만 아니라 적당한 집합으로 사용될 수 있다. The pharmaceutical dosage form of the antimicrobial substance of the present application may be used in the form of a pharmaceutically acceptable salt thereof, and may be used alone or in combination with other pharmaceutically active compounds as well as in an appropriate group.
또 하나의 양태로서, 본 출원은 상기 미생물 감염 질환의 예방 또는 치료용 조성물을 개체에 투여하는 단계를 포함하는 미생물 감염 질환의 예방 또는 치료 방법을 제공한다. 본 출원에서 사용되는 용어, "개체"란, 미생물 감염 질환이 발병되었거나 발병할 가능성이 있는 인간을 포함한 모든 동물을 의미할 수 있다.As another aspect, the present application provides a method for preventing or treating a microbial infectious disease comprising administering to an individual a composition for preventing or treating the microbial infectious disease. As used herein, the term "individual" may mean any animal, including humans, that has or is likely to develop a microbial infection disease.
본 출원의 상기 예방 또는 치료 방법은 구체적으로, 미생물 감염 질환이 발병하였거나 발병할 위험이 있는 개체에 상기 조성물을 약학적으로 유효한 양으로 투여하는 단계를 포함할 수 있다.Specifically, the prevention or treatment method of the present application may include administering the composition in a pharmaceutically effective amount to an individual having or at risk of developing a microbial infection disease.
상기 추출물을 포함하는 조성물의 적합한 총 1일 사용량은 올바른 의학적 판단 범위 내에서 처치의에 의해 결정될 수 있으며, 1회 또는 수회로 나누어 투여할 수 있다. 그러나 본 출원의 목적상, 특정 환자에 대한 구체적인 치료적 유효량은 달성하고자 하는 반응의 종류와 정도, 경우에 따라 다른 제제가 사용되는지의 여부를 비롯한 구체적 조성물, 환자의 연령, 체중, 일반 건강 상태, 성별 및 식이, 투여 시간, 투여 경로 및 조성물의 분비율, 치료기간, 구체적 조성물과 함께 사용되거나 동시 사용되는 약물을 비롯한 다양한 인자와 의약 분야에 잘 알려진 유사 인자에 따라 다르게 적용하는 것이 바람직하다.A suitable total daily amount of the composition containing the extract may be determined by the treating physician within the scope of correct medical judgment, and may be administered once or divided into several doses. However, for the purposes of the present application, a specific therapeutically effective amount for a particular patient depends on the type and extent of the response to be achieved, the specific composition, including whether other agents are used in some cases, the patient's age, weight, general health, It is preferable to apply differently depending on various factors including sex and diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field.
본 출원의 항균물질은 쥐, 생쥐, 가축, 인간 등의 포유동물에 다양한 경로로 투여될 수 있다. 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 (intracerebroventricular) 주사에 의해 투여될 수 있다. The antimicrobial substance of the present application may be administered to mammals such as rats, mice, livestock, and humans by various routes. Any mode of administration can be envisaged, for example, by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injection.
또 하나의 양태로서, 본 출원은 상기 항균 조성물을 포함하는 미생물 감염 질환의 예방 또는 개선용 건강기능식품을 제공한다.As another aspect, the present application provides a health functional food for preventing or improving microbial infectious diseases comprising the antibacterial composition.
이 때, 미생물 감염 질환, 예방, 및 개선의 의미는 상기한 바와 같다.At this time, the meaning of microbial infection disease, prevention, and improvement is as described above.
본 출원의 용어, "건강기능식품 (Health functional food 또는 nutraceutical)"은, 특정보건용 식품, 기능성 식품, 건강식품과 동일한 용어로, 양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미하는데, 상기 식품은 탈모 관련 질환의 예방 또는 개선에 유용한 효과를 얻기 위하여 정제, 캡슐, 분말, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.As used herein, the term "health functional food (health functional food or nutraceutical)" is the same term as food for specific health, functional food, and health food. It means a food with high effect, and the food may be prepared in various forms such as tablets, capsules, powders, granules, liquids, pills, etc. to obtain a useful effect for preventing or improving hair loss-related diseases.
상기 건강기능식품은 식품학적으로 허용되는 담체를 포함할 수 있으며, 이는 전술한 바와 같다. The health functional food may include a food-logically acceptable carrier, which is as described above.
본 출원의 건강기능식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 출원의 건강기능식품은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 출원의 건강기능식품은 미생물 감염 질환의 예방 또는 개선효과를 증진시키기 위한 보조제로 섭취가 가능하다.The health functional food of the present application can be manufactured by a method commonly used in the art, and at the time of manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, if the formulation of the health functional food is also recognized as a health functional food, it may be manufactured without limitation. The health functional food of the present application can be manufactured in various forms, and unlike general drugs, it has the advantage that there are no side effects that may occur during long-term administration of the drug by using food as a raw material, and has excellent portability. health functional food can be consumed as a supplement to enhance the prevention or improvement effect of microbial infections.
구체적으로, 상기 식품은 상기 항균조성물을 음료, 차류, 향신료, 껌, 과자류 등의 식품소재에 첨가하거나, 캡슐화, 분말화, 현탁액 등으로 제조한 식품으로, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등으로 사용될 수 있다. Specifically, the food is a food prepared by adding the antimicrobial composition to food materials such as beverages, teas, spices, gum, and confectionery, or encapsulating, powdering, suspension, etc., for example, various foods, beverages, gum , tea, vitamin complex, health functional food, etc.
상기 식품은 공지의 제조방법에 따라 정제, 과립, 분말, 캅셀, 액상의 용액 및 환 등의 제형으로 제조할 수 있으며, 본 출원에 따른 조성물의 함량은 제형에 따라 조절할 수 있다. 본 출원에 의한 항균 조성물을 유효성분으로 함유하는 외에는 다른 성분에는 특별한 제한이 없으며, 통상의 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.The food can be prepared in dosage forms such as tablets, granules, powders, capsules, liquid solutions and pills according to a known manufacturing method, and the content of the composition according to the present application can be adjusted according to the dosage form. There is no particular limitation on other ingredients other than containing the antimicrobial composition according to the present application as an active ingredient, and various conventional flavoring agents or natural carbohydrates may be included as additional ingredients.
또 하나의 양태로서, 본 출원은 상기 항균 조성물을 포함하는 의약외품 조성물을 제공한다.As another aspect, the present application provides a quasi-drug composition comprising the antibacterial composition.
본 출원에서 용어, "의약외품"은 사람이나 동물의 질병을 치료, 경감, 처치 또는 예방할 목적을 사용되는 섬유, 고무제품 또는 이와 유사한 것, 인체에 대한 작용이 약하거나 인체에 직접 작용하지 아니하며, 기구 또는 기계가 아닌 것과 이와 유사한 것, 감염형 예방을 위하여 살균, 살충 및 이와 유사한 용도로 사용되는 제제 중 하나에 해당하는 물품으로서, 사람이나 동물의 질병을 진단, 치료, 경감, 처치 또는 예방할 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것 및 사람이나 동물의 구조와 기능에 약리학적 영향을 줄 목적으로 사용하는 물품 중 기구, 기계 또는 장치가 아닌 것을 제외한 물품을 의미할 수 있다. 또한 상기 의약외품은 피부외용제 및 개인위생용품을 포함할 수 있다. 바람직하게는 소독청결제, 샤워폼, 가그린, 물티슈, 세제비누, 핸드워시, 또는 연고제일 수 있으나 이에 제한되지는 않는다.In the present application, the term "quasi-drug" refers to fibers, rubber products, or the like, which are used for the purpose of treating, alleviating, treating or preventing diseases of humans or animals, have weak action on the human body, or do not directly act on the human body. or non-machines and the like, as an article corresponding to one of the preparations used for sterilization, insecticide and similar purposes for the prevention of infection type, for the purpose of diagnosing, treating, alleviating, treating or preventing diseases of humans or animals It can refer to items other than instruments, machines, or devices, and items used for the purpose of pharmacologically affecting the structure and function of humans or animals, excluding those that are not instruments, machines, or devices. In addition, the quasi-drugs may include external preparations for skin and personal care products. Preferably, it may be a disinfectant cleaner, shower foam, gargrin, wet tissue, detergent soap, hand wash, or ointment, but is not limited thereto.
상기 의약외품 조성물은 약학적으로 허용되는 담체를 포함할 수 있으며, 이는 전술한 바와 같다. The quasi-drug composition may include a pharmaceutically acceptable carrier, as described above.
본 발명자들은 신규 분리된 리조푸스 올리고스포러스 CJCC02-20는 상기 진균 및 세균에 대한 항균효과를 가짐을 확인하였는바, 상기 신규 균주를 이용한 항균 조성물은 의약외품에 효과적으로 사용될 수 있다.The present inventors have confirmed that the newly isolated Rhizopus oligosporus CJCC02-20 has an antibacterial effect on the fungi and bacteria, and the antibacterial composition using the novel strain can be effectively used for quasi-drugs.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 항균조성물을 포함하는 사료 조성물을 제공한다. As another aspect for achieving the above object, the present application provides a feed composition comprising the antibacterial composition.
본 출원에서 용어, "사료"는 동물이 먹고, 섭취하며, 소화시키기 위한 또는 이에 적당한 임의의 천연 또는 인공 규정식, 한끼식 등 또는 상기 한끼식의 성분을 의미할 수 있다.As used herein, the term “feed” may refer to any natural or artificial diet, one meal, etc., or a component of the one meal meal, for or suitable for the animal to eat, ingest, and digest.
상기 사료의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용되는 사료를 사용할 수 있다. 상기 사료용 조성물은 사료 첨가제를 포함할 수 있다. 본 출원의 사료첨가제는 사료관리법상의 보조사료에 해당하며, 생균제를 포함할 수 있다. 상기 사료의 비제한적인 예로는, 곡물류, 근과류, 식품 가공 부산물류, 조류, 섬유질류, 제약 부산물류, 유지류, 전분류, 박류 또는 곡물 부산물류 등과 같은 식물성 사료; 단백질류, 무기물류, 유지류, 광물성류, 유지류, 단세포 단백질류, 동물성 플랑크톤류 또는 음식물 등과 같은 동물성 사료를 들 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.The type of feed is not particularly limited, and feed commonly used in the art may be used. The composition for feed may include a feed additive. The feed additive of the present application corresponds to an auxiliary feed under the Feed Management Act, and may include probiotics. Non-limiting examples of the feed include plant feeds such as grains, root fruits, food processing by-products, algae, fibers, pharmaceutical by-products, oils and fats, starches, gourds or grain by-products; and animal feeds such as proteins, inorganic materials, oils and fats, minerals, oils and fats, single cell proteins, zooplankton or food. These may be used alone or in mixture of two or more.
이때, 본 출원의 항균조성물을 포함하는 사료 조성물은 부형제, 희석제, 첨가제를 더 포함할 수 있다.In this case, the feed composition including the antimicrobial composition of the present application may further include an excipient, a diluent, and an additive.
본 출원의 신규 분리된 리조푸스 올리고스포러스 CJCC02-20가 곰팡이 균인 아스퍼질러스 오리재, 아스퍼질러스 나이거 및 식중독 세균인 바실러스 세레우스, 대장균을 동시에 억제할 수 있는 효과가 있음을 확인하였는바, 본 출원은 항균 및 항진균 활성이 있는 사료 조성물을 제공하여, 가축의 식중독을 포함한 미생물 감염 질환을 예방할 수 있다.It was confirmed that the newly isolated Rhizopus oligosporus CJCC02-20 of the present application has the effect of simultaneously inhibiting the fungi Aspergillus duckjae, Aspergillus niger and the food poisoning bacteria Bacillus cereus and Escherichia coli. , The present application provides a feed composition having antibacterial and antifungal activity, thereby preventing microbial infection diseases including food poisoning of livestock.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 신규 분리된 리조푸스 올리고스포러스 CJCC02-20을 배지에서 배양하는 단계를 포함하는, 항균 조성물의 제조방법을 제공한다. As another aspect for achieving the above object, the present application provides a method for producing an antibacterial composition, comprising the step of culturing the newly isolated Rhizopus oligosporus CJCC02-20 in a medium.
본 출원에서, 용어 "배양"은 본 출원의 리조푸스 올리고스포러스 CJCC02-20을 적당히 조절된 환경 조건에서 생육시키는 것을 의미한다. 본 출원의 배양과정은 당업계에 알려진 적당한 배지와 배양조건에 따라 이루어질 수 있다. 이러한 배양 과정은 선택되는 균주에 따라 당업자가 용이하게 조정하여 사용할 수 있다. 구체적으로 상기 배양은 회분식, 연속식 및/또는 유가식일 수 있으나, 이에 제한되는 것은 아니다.In the present application, the term "cultivation" means growing the Rhizopus oligosporus CJCC02-20 of the present application under moderately controlled environmental conditions. The culturing process of the present application may be made according to a suitable medium and culture conditions known in the art. Such a culture process can be easily adjusted and used by those skilled in the art according to the selected strain. Specifically, the culture may be a batch, continuous and/or fed-batch, but is not limited thereto.
본 출원에서 용어, "배지"는 본 출원의 리조푸스 올리고스포러스 CJCC02-20을 배양하기 위해 필요로 하는 영양물질을 주성분으로 혼합한 물질을 의미하며, 생존 및 발육에 불가결한 물을 비롯하여 영양물질 및 발육인자 등을 공급한다. 구체적으로, 본 출원의 리조푸스 올리고스포러스 CJCC02-20의 배양에 사용되는 배지 및 기타 배양 조건은 통상의 미생물의 배양에 사용되는 배지라면 특별한 제한 없이 어느 것이나 사용할 수 있으나, 본 출원의 리조푸스 올리고스포러스 CJCC02-20을 적당한 탄소원, 질소원, 인원, 무기화합물, 아미노산 및/또는 비타민 등을 함유한 통상의 배지 내에서 호기성 조건 하에서 온도, pH 등을 조절하면서 배양할 수 있다. As used herein, the term "medium" refers to a material in which nutrients required for culturing Rhizopus oligosporus CJCC02-20 of the present application are mixed as a main component, and nutrients including water essential for survival and development and growth factors. Specifically, the medium and other culture conditions used for culturing the Rhizopus oligosporus CJCC02-20 of the present application may be used without any particular limitation as long as the medium used for culturing conventional microorganisms, but the Rhizopus oligo of the present application Sporus CJCC02-20 can be cultured under aerobic conditions while controlling temperature, pH, etc. in a normal medium containing an appropriate carbon source, nitrogen source, phosphorus, inorganic compound, amino acid and/or vitamin.
본 출원에서 상기 탄소원으로는 글루코오스, 사카로오스, 락토오스, 프룩토오스, 수크로오스, 말토오스 등과 같은 탄수화물; 만니톨, 소르비톨 등과 같은 당 알코올, 피루브산, 락트산, 시트르산 등과 같은 유기산; 글루탐산, 메티오닌, 리신 등과 같은 아미노산 등이 포함될 수 있다. 또한, 전분 가수분해물, 당밀, 블랙스트랩 당밀, 쌀겨울, 카사버, 사탕수수 찌꺼기 및 옥수수 침지액 같은 천연의 유기 영양원을 사용할 수 있으며, 구체적으로는 글루코오스 및 살균된 전처리 당밀(즉, 환원당으로 전환된 당밀) 등과 같은 탄수화물이 사용될 수 있으며, 그 외의 적정량의 탄소원을 제한 없이 다양하게 이용할 수 있다. 이들 탄소원은 단독으로 사용되거나 2 종 이상이 조합되어 사용될 수 있으며, 이에 한정되는 것은 아니다.As the carbon source in the present application, carbohydrates such as glucose, saccharose, lactose, fructose, sucrose, maltose; sugar alcohols such as mannitol and sorbitol; organic acids such as pyruvic acid, lactic acid, citric acid and the like; Amino acids such as glutamic acid, methionine, lysine, and the like may be included. In addition, natural organic nutrient sources such as starch hydrolyzate, molasses, blackstrap molasses, rice winter, cassava, sugar cane offal and corn steep liquor can be used, specifically glucose and sterilized pre-treated molasses (i.e., converted to reducing sugar). molasses) may be used, and other appropriate amounts of carbon sources may be variously used without limitation. These carbon sources may be used alone or in combination of two or more, but is not limited thereto.
상기 질소원으로는 암모니아, 황산암모늄, 염화암모늄, 초산암모늄, 인산암모늄, 탄산안모늄, 질산암모늄 등과 같은 무기질소원; 글루탐산, 메티오닌, 글루타민 등과 같은 아미노산, 펩톤, NZ-아민, 육류 추출물, 효모 추출물, 맥아 추출물, 옥수수 침지액, 카세인 가수분해물, 어류 또는 그의 분해생성물, 탈지 대두 케이크 또는 그의 분해 생성물 등과 같은 유기 질소원이 사용될 수 있다. 이들 질소원은 단독으로 사용되거나 2 종 이상이 조합되어 사용될 수 있으며, 이에 한정되는 것은 아니다.Examples of the nitrogen source include inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, anmonium carbonate, and ammonium nitrate; Amino acids such as glutamic acid, methionine, glutamine, and organic nitrogen sources such as peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolyzate, fish or degradation products thereof, defatted soybean cake or degradation products thereof, etc. can be used These nitrogen sources may be used alone or in combination of two or more, but is not limited thereto.
상기 인원으로는 인산 제1칼륨, 인산 제2칼륨, 또는 이에 대응되는 소디움-함유 염 등이 포함될 수 있다. 무기화합물로는 염화나트륨, 염화칼슘, 염화철, 황산마그네슘, 황산철, 황산망간, 탄산칼슘 등이 사용될 수 있으며, 그 외에 아미노산, 비타민 및/또는 적절한 전구체 등이 포함될 수 있다. 이들 구성성분 또는 전구체는 배지에 회분식 또는 연속식으로 첨가될 수 있다. 그러나, 이에 한정되는 것은 아니다.The phosphorus may include potassium first potassium phosphate, second potassium phosphate, or a sodium-containing salt corresponding thereto. As the inorganic compound, sodium chloride, calcium chloride, iron chloride, magnesium sulfate, iron sulfate, manganese sulfate, calcium carbonate, etc. may be used, and in addition, amino acids, vitamins and/or appropriate precursors may be included. These components or precursors may be added to the medium either batchwise or continuously. However, the present invention is not limited thereto.
또한, 본 출원의 리조푸스 올리고스포러스 CJCC02-20의 배양 중에 수산화암모늄, 수산화칼륨, 암모니아, 인산, 황산 등과 같은 화합물을 배지에 적절한 방식으로 첨가하여, 배지의 pH를 조정할 수 있다. 또한, 배양 중에는 지방산 폴리글리콜 에스테르와 같은 소포제를 사용하여 기포 생성을 억제할 수 있다. 또한, 배지의 호기 상태를 유지하기 위하여, 배지 내로 산소 또는 산소 함유 기체를 주입하거나 혐기 및 미호기 상태를 유지하기 위해 기체의 주입 없이 혹은 질소, 수소 또는 이산화탄소 가스를 주입할 수 있으며, 이에 한정되는 것은 아니다.In addition, during the culture of Rhizopus oligosporus CJCC02-20 of the present application, compounds such as ammonium hydroxide, potassium hydroxide, ammonia, phosphoric acid, sulfuric acid, etc. may be added to the medium in an appropriate manner to adjust the pH of the medium. In addition, during culturing, an antifoaming agent such as fatty acid polyglycol ester may be used to suppress bubble formation. In addition, in order to maintain the aerobic state of the medium, oxygen or oxygen-containing gas may be injected into the medium, or nitrogen, hydrogen or carbon dioxide gas may be injected without injection of gas or without injection of gas to maintain anaerobic and microaerobic conditions, which are limited thereto. it is not
본 출원의 배양에서 배양온도는 20 내지 45℃구체적으로는 25 내지 40℃를 유지할 수 있고, 약 10 내지 160 시간 동안 배양할 수 있으나, 이에 한정되는 것은 아니다. In the culture of the present application, the culture temperature may be maintained at 20 to 45 °C, specifically, 25 to 40 °C, and may be cultured for about 10 to 160 hours, but is not limited thereto.
본 출원의 항균조성물의 제조방법은, 본 출원의 리조푸스 올리고스포러스 CJCC02-20 균주를 준비하는 단계, 상기 균주를 배양하기 위한 배지를 준비하는 단계, 또는 이들의 조합(순서에 무관, in any order)을, 예를 들어, 상기 배양하는 단계 이전에, 추가로 포함할 수 있다. The method for preparing the antimicrobial composition of the present application includes the steps of preparing the Rhizopus oligosporus CJCC02-20 strain of the present application, preparing a medium for culturing the strain, or a combination thereof (regardless of the order, in any order), for example, before the culturing step, may further include.
본 출원의 항균조성물의 제조방법은, 상기 배양에 따른 배지(배양이 수행된 배지) 또는 본 출원의 리조푸스 올리고스포러스 CJCC02-20 균주로부터 항균물질을 회수하는 단계를 추가로 포함할 수 있다. 상기 회수하는 단계는 상기 배양하는 단계 이후에 추가로 포함될 수 있다.The method for preparing the antibacterial composition of the present application may further include recovering the antimicrobial material from the culture medium (cultured medium) or the Rhizopus oligosporus CJCC02-20 strain of the present application. The recovering step may be further included after the culturing step.
이때, 상기 항균물질은 리조푸스 올리고스포러스 CJCC02-20 균주가 생산하는 항균활성을 가지는 물질이면 제한 없이 모두 포함되며, 일 구체예로 추출액(crude extracts), 화합물 일 수 있으나 이에 제한 되는 것은 아니다. At this time, the antibacterial material is included without limitation as long as it is a material having antibacterial activity produced by the Rhizopus oligosporus CJCC02-20 strain, and in one embodiment, it may be crude extracts or a compound, but is not limited thereto.
상기 회수는 본 출원의 미생물의 배양 방법, 예를 들어 회분식, 연속식 또는 유가식 배양 방법 등에 따라 당해 기술 분야에 공지된 적합한 방법을 이용하여 목적하는 항균물질을 수집(collect)하는 것일 수 있다. 예를 들어, 원심분리, 여과, 결정화 단백질 침전제에 의한 처리(염석법), 추출, 초음파 파쇄, 한외여과, 투석법, 분자체 크로마토그래피(겔여과), 흡착크로마토그래피, 이온교환 크로마토그래피, 친화도 크로마토그래피 등의 각종 크로마토그래피, HPLC 또는 이들의 방법을 조합하여 사용될 수 있으며, 당해 분야에 공지된 적합한 방법을 이용하여 배지 또는 미생물로부터 목적하는 항균물질을 회수할 수 있다.The recovery may be to collect the desired antibacterial material using a suitable method known in the art according to the culture method of the microorganism of the present application, for example, a batch, continuous or fed-batch culture method. For example, centrifugation, filtration, treatment with a crystallized protein precipitating agent (salting out method), extraction, ultrasonic disruption, ultrafiltration, dialysis, molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity Various chromatography such as island chromatography, HPLC, or a combination thereof may be used, and a desired antimicrobial substance may be recovered from the medium or microorganism using a suitable method known in the art.
또한, 본 출원의 항균조성물의 제조방법은, 추가적으로 정제 단계를 포함할 수 있다. 상기 정제는 당해 기술분야에 공지된 적합한 방법을 이용하여, 수행할 수 있다. 일 예에서, 본 출원의 항균조성물 제조방법이 회수 단계와 정제 단계를 모두 포함하는 경우, 상기 회수 단계와 정제 단계는 순서에 상관없이 이시적(또는 연속적)으로 수행되거나, 동시에 또는 하나의 단계로 통합되어 수행될 수 있으나, 이에 제한되는 것은 아니다.In addition, the method for preparing the antimicrobial composition of the present application may additionally include a purification step. The purification may be performed using a suitable method known in the art. In one example, when the method for preparing the antimicrobial composition of the present application includes both the recovery step and the purification step, the recovery step and the purification step are performed concurrently (or continuously) regardless of the order, or simultaneously or in one step It may be integrated and performed, but is not limited thereto.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 신규 분리된 리조푸스 올리고스포러스 CJCC02-20 균주 또는 상기 균주를 이용한 발효물을 포함하는 식품 조성물을 제공한다.As another aspect for achieving the above object, the present application provides a food composition comprising the novel isolated Rhizopus oligosporus CJCC02-20 strain or a fermented product using the strain.
상기 리조푸스 올리고스포러스 CJCC02-20 및 식품은 전술된 바와 같다.The Rhizopus oligosporus CJCC02-20 and food are as described above.
본 출원의 용어, "발효물"은 식품의 주원료를 함유하고 있는 배지에 리조푸스 올리고스포러스 CJCC02-20 균주를 접종 및 배양하여 수득한 배지 또는 상기 배지와 함께 배양한 미생물을 포함하는 배양물을 의미한다.As used herein, the term "fermented product" refers to a medium obtained by inoculating and culturing the Rhizopus oligosporus CJCC02-20 strain in a medium containing the main raw material of food or a culture containing a microorganism cultured with the medium. it means.
또한 상기 발효물은 식품 원료에 리조푸스 올리고스포러스 CJCC02-20 균주를 접종 및 배양하여 수득한 배양물일 수 있다. 상기 식품 원료는 곡물류일 수 있으며, 이에 제한되지 않는다.In addition, the fermented product may be a culture obtained by inoculating and culturing the Rhizopus oligosporus CJCC02-20 strain in the food raw material. The food raw material may be grains, but is not limited thereto.
본 출원의 일 구체예로 상기 곡물류는 쌀, 보리, 밀, 옥수수 등일 수 있으며, 구체적으로, 밀, 밀브랜, 쌀 일 수 있으나, 이에 제한되지 않는다. In one embodiment of the present application, the grains may be rice, barley, wheat, corn, and the like, and specifically, may be wheat, wheat bran, or rice, but is not limited thereto.
상기 발효물은 상기 배지 또는 배양물의 여과액, 희석액, 이들의 농축액, 이들의 조정제물, 정제물, 건조물, 분쇄물 등을 모두 포함하는 것으로 포괄적으로 해석될 수 있으나, 이에 제한되지 않는다.The fermented product may be comprehensively interpreted as including all of the filtrate, dilution, and concentrate thereof, purified product, dried product, pulverized product, and the like of the medium or culture, but is not limited thereto.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 신규 분리된 균주 리조푸스 올리고스포러스 CJCC02-20을 접종하는 단계를 포함하는 식품의 제조방법을 제공한다. As another aspect for achieving the above object, the present application provides a method for producing a food comprising the step of inoculating the newly isolated strain Rhizopus oligosporus CJCC02-20.
상기 리조푸스 올리고스포러스 CJCC02-20 및 식품은 전술된 바와 같다.The Rhizopus oligosporus CJCC02-20 and food are as described above.
본 출원의 일 구체예로, 상기 식품 제조방법은 상기 리조푸스 올리고스포러스 CJCC02-20을 곡물에 접종 및 배양하는 단계를 포함하는 발효식품의 제조방법일 수 있다. 상기 균주를 접종 및 배양하여 수득한 발효식품은 구체적으로 장류, 젓갈류 일 수 있으며, 보다 구체적으로 템페 또는 템페를 포함하는 소스류일 수 있으나 이에 제한되는 것은 아니다. In one embodiment of the present application, the food manufacturing method may be a manufacturing method of a fermented food comprising the step of inoculating and culturing grains with the Rhizopus oligosporus CJCC02-20. The fermented food obtained by inoculating and culturing the strain may be specifically soy sauce or salted fish, and more specifically, may be tempeh or a sauce containing tempeh, but is not limited thereto.
상기의 목적을 달성하기 위한 또 다른 양태로서, 본 출원은 상기 신규 분리된 균주 리조푸스 올리고스포러스 CJCC02-20을 포함하는 사료 조성물을 제공한다. As another aspect for achieving the above object, the present application provides a feed composition comprising the novel isolated strain Rhizopus oligosporus CJCC02-20.
상기 리조푸스 올리고스포러스 CJCC02-20 및 사료는 전술된 바와 같다.The Rhizopus oligosporus CJCC02-20 and feed are the same as described above.
본 출원에 따른 리조푸스 올리고스포러스 CJCC02-20균주를 포함하는 항균 조성물은 진균 및 세균에 대하여 항균 활성을 지니는 특성을 가지므로 식품, 의약품, 의약외품, 건강기능식품 등으로 유용하게 사용할 수 있다.Since the antibacterial composition comprising the Rhizopus oligosporus CJCC02-20 strain according to the present application has antibacterial activity against fungi and bacteria, it can be usefully used as food, medicine, quasi-drug, health functional food, etc.
도 1은 디스크여지법 (paper disk assay)을 이용하여 리조푸스 올리고스포러스 CJCC02-20균주의 아스퍼질러스 오리재, 아스퍼질러스 나이거 및 대장균에 대한 항균 활성을 측정한 결과이다. 1 is a result of measuring the antibacterial activity against Aspergillus duckjae, Aspergillus niger and E. coli of Rhizopus oligosporus CJCC02-20 strain using a paper disk assay.
이하, 실시예를 통해 본 출원의 구성 및 효과를 더욱 상세하게 설명하고자 하나, 이들 실시예는 본 출원의 예시적인 기재일 뿐, 본 출원의 범위가 이들 실시예에만 한정되는 것은 아니다.Hereinafter, the configuration and effects of the present application will be described in more detail through examples, but these examples are only exemplary descriptions of the present application, and the scope of the present application is not limited only to these examples.
실시예 1. 항균 물질을 생산하는 균주의 분리 및 동정Example 1. Isolation and identification of strains producing antibacterial substances
항균 활성이 있는 균주의 선별을 위하여, 재래식 템페들을 PDA (Potato Dextrose Agar) 배지에서 30℃ 5일 배양한 후 리조푸스 속 형태적 특징을 이용하여 1차 선별하고, 선별된 균주는 5% Kanamycin 1,000ppm을 넣은 PDA 배지에 30℃ 5일 간 배양하여 분리하였다. For the selection of strains with antibacterial activity, conventional tempes were cultured in PDA (Potato Dextrose Agar) medium for 5 days at 30° C. It was isolated by culturing for 5 days at 30°C in PDA medium containing ppm.
상기와 같은 공정에 의해 선별된 균주의 18S rRNA, ABP (ABP1) 및 Chitinase (Chi2) 유전자의 염기서열을 분석하였다. 염기서열은 NCBI의 BLAST를 이용하여 GenBank 데이터베이스와 선별된 균주의 각각의 염기서열(18S rRNA: 서열 번호 1, ABP1: 서열 번호 2, Chi2: 서열 번호 3)을 비교하였다. The nucleotide sequences of 18S rRNA, ABP (ABP1) and Chitinase (Chi2) genes of the strains selected by the above process were analyzed. For the nucleotide sequence, the GenBank database and each nucleotide sequence of the selected strains (18S rRNA: SEQ ID NO: 1, ABP1: SEQ ID NO: 2, Chi2: SEQ ID NO: 3) were compared using BLAST of NCBI.
구체적으로, ABP1 유전자의 염기서열에 근거하여 프라이머 서열번호 4 및 5를 합성하였으며, Chi2 유전자의 염기서열에 근거하여 프라이머 서열번호 6 및 7을 합성하여 PCR을 통해 각각의 염기서열을 확인하였다. 그 결과, 본 균주의 염기서열은 리조푸스 올리고스포러스 18S rRNA에 대해 100%, ABP Gene에 대해 99.9%, Chitinase Gene에 대해 100% 상동성을 보였다.Specifically, primers SEQ ID NOs: 4 and 5 were synthesized based on the nucleotide sequence of the ABP1 gene, and primers SEQ ID NOs: 6 and 7 were synthesized based on the nucleotide sequence of the Chi2 gene to confirm each nucleotide sequence through PCR. As a result, the nucleotide sequence of this strain showed 100% homology to Rhizopus oligosporus 18S rRNA, 99.9% to ABP Gene, and 100% homology to Chitinase Gene.
상기의 결과로부터 본 출원에서 수득된 균주는 리조푸스 올리고스포러스 균주로 동정하고 리조푸스 올리고스포러스 CJCC02-20로 명명하였으며, 부다페스트 조약 하의 국제기탁기관인 한국미생물보존센터(KCCM)에 2020년 12월 09일자로 기탁하고 수탁번호 KCCM12893P를 부여 받았다. The strain obtained in this application from the above results was identified as a Rhizopus oligosporus strain and named as Rhizopus oligosporus CJCC02-20, and was transferred to the Korea Center for Microorganisms Conservation (KCCM), an international depository under the Budapest Treaty, in December 2020. It was deposited on the 09th and was given an accession number KCCM12893P.
실시예 2. 항균 물질의 분리 및 정제Example 2. Isolation and Purification of Antimicrobial Substances
신규 분리된 리조푸스 올리고스포러스 CJCC02-20균주가 생산하는 항균물질을 분리하고자, 상기 균주를 10-15 g 밀브랜에 접종한 다음, 30℃ 5일, 35℃ 1일간 배양하였다. 상기 배양물을 증류수 중량 50배 희석 후 60분간 30℃ 150 rpm 조건으로 추출하였다. 추출액(crude extracts)은 규조토를 이용하여 5.0 μm Filter paper로 감압 여과를 행하였다. 여과액은 -20℃ 48시간 동결 건조하여 건조물로 정제하였다. In order to isolate the antibacterial material produced by the newly isolated Rhizopus oligosporus CJCC02-20 strain, 10-15 g of the strain was inoculated into wheat bran, and then cultured at 30°C for 5 days and at 35°C for 1 day. The culture was diluted 50 times by weight of distilled water and then extracted at 30° C. and 150 rpm for 60 minutes. The crude extracts were filtered under reduced pressure with 5.0 μm filter paper using diatomaceous earth. The filtrate was freeze-dried at -20°C for 48 hours and purified to dryness.
실시예 3. 진균류 및 식중독 유발 세균에 대한 항균 활성 시험Example 3. Antibacterial activity test against fungi and food poisoning-causing bacteria
신규 분리된 리조푸스 올리고스포러스 CJCC02-20균주가 진균류 및 식중독 유발 세균에 대하여 억제하는 효과가 있는지 확인하기 위하여 아래와 같은 항균 활성 실험을 진행하였다. In order to check whether the newly isolated strain of Rhizopus oligosporus CJCC02-20 has an inhibitory effect on fungi and food poisoning-causing bacteria, the following antibacterial activity test was conducted.
장류 발효 곰팡이인 아스퍼질러스 오리재 (Aspergillus oryzae)와 식품 오염원 아스퍼질러스 나이거 (Aspergillus niger)는 PDA (Potato dextrose agar) 배지에 배양하였다. Aspergillus oryzae, a paste fermenting mold, and Aspergillus niger, a food contaminant, were cultured in PDA (Potato dextrose agar) medium.
병원성 효모균 칸디다 알비칸스(Candida albicans)와 식품 오염원 자이고사카로마이세스 바일리(Zygosaccharomyces bailii) 들은 YPD 배지(Yeast extract peptone dextrose agar)에 배양하였다. The pathogenic yeast Candida albicans and the food contaminant Zygosaccharomyces bailii were cultured in YPD medium (Yeast extract peptone dextrose agar).
또한, 식중독 유발 세균인 바실러스 세레우스(Bacillus cereus), 장관병원성 대장균(Escherichia coli), 장류 발효 세균인 바실러스 서브틸리스(Bacillus subtilis), 바실러스 벨레젠시스 (Bacillus velezensis) 들은 TSA(Tryptic soy agar) 배지에 배양하였다.In addition, food poisoning-causing bacteria Bacillus cereus, enteropathogenic Escherichia coli, enteric fermentation bacteria Bacillus subtilis, Bacillus velezensis (Bacillus velezensis) are TSA (Tryptic soy agar) Cultured in medium.
상기 실시예 2에서 건조한 항균 물질을 증류수에 녹인 후, 상기 지시 균주가 도말된 평판배지 위에 8 mm 직경의 종이 디스크를 놓고 상기 항균 물질을 30 μl씩 일정하게 가한 후에 30℃에서 24 내지 48시간 동안 배양하여 분리 균주가 생산하는 항균 물질에 의한 생육 저지환 생성 여부를 관찰하였으며, 그 결과를 표 1및 도 1에 나타내었다. 상기 표 1의 '-'는 생육을 저지하지 못한 경우이고, '+'의 경우 생육 저지환의 직경이 3mm 내지 5 mm이하인 경우이고, '++'의 경우 생육 저지환의 직경이 6mm 내지 10mm인 경우이며, '+++'의 경우 생육 저지환의 직경이 10 mm 이상인 경우이다.After dissolving the dried antibacterial material in distilled water in Example 2, a paper disk of 8 mm diameter is placed on the plate medium on which the indicator strain is smeared, and 30 μl of the antibacterial material is constantly added thereto at 30° C. for 24 to 48 hours. By culturing, it was observed whether or not growth-preventing rings were generated by the antibacterial material produced by the isolated strain, and the results are shown in Table 1 and FIG. 1 . '-' in Table 1 is a case in which growth is not inhibited, in the case of '+', the diameter of the growth-stopping ring is 3 mm to 5 mm or less, and in the case of '++', the diameter of the growth-stopping ring is 6 mm to 10 mm. And, in the case of '+++', the diameter of the growth-stopping ring is 10 mm or more.
또한, 상기 리조푸스 올리고스포러스 CJCC02-20균주 외에 재래식 템페(인도네시아 및 베트남에서 전통방식으로 제조한 템페)에서 분리한 균주인 리조푸스 올리고스포러스 균주 4종을 비교예 1 내지 4로 항균활성을 비교하였다. In addition, in addition to the above Rhizopus oligosporus CJCC02-20 strain, 4 types of Rhizopus oligosporus strains, which are strains isolated from conventional tempeh (tempe prepared in a traditional way in Indonesia and Vietnam), were tested for antibacterial activity in Comparative Examples 1 to 4. compared.
상기 표 1 및 도 1에서 확인할 수 있듯이, 리조푸스 올리고스포러스 CJCC02-20균주로부터 수득한 정제 물질은 효모에는 항균 활성이 없었으나, 장류 또는 일반 식품에서 저해하기 어려운 아스퍼질러스 오리재와 아스퍼질러스 나이거 곰팡이 균을 선택적으로 제어할 수 있는 우수한 항진균 활성을 보였다. As can be seen in Table 1 and Figure 1, the purified material obtained from the Rhizopus oligosporus CJCC02-20 strain did not have antibacterial activity in yeast, but Aspergillus duck material and Aspergillus, which are difficult to inhibit in soybeans or general foods. It showed excellent antifungal activity to selectively control snigger mold bacteria.
또한, 장관병원성 대장균에 선택적 항균 활성을 보였으며, 타 리조푸스 올리고스포러스 균주 대비 식중독균인 바실러스 세레우스에 대한 항균활성이 뛰어남을 확인할 수 있었다. In addition, it showed selective antibacterial activity against enteropathogenic E. coli, and it was confirmed that the antibacterial activity against Bacillus cereus, a food poisoning bacterium, was excellent compared to other Rhizopus oligosporus strains.
실시예 4: 발효제품 템페에서 식중독균 방제 효과 확인Example 4: Confirmation of the effect of controlling food poisoning bacteria in the fermented product tempe
실시예 1에 의해 동정된 리조푸스 올리고스포러스 CJCC02-20의 발효제품에서 의 식중독균 방제효과를 확인하기 위하여, 리조푸스 올리고스포러스 CJCC02-20균주를 15-20 g 밀쌀에 접종한 다음, 30℃ 6일, 40℃ 1일간 배양하였다. 상기 배양물은 분쇄기를 이용하여 분말로 만들었다. In order to confirm the effect of controlling food poisoning bacteria in the fermented product of Rhizopus oligosporus CJCC02-20 identified in Example 1, 15-20 g of Rhizopus oligosporus CJCC02-20 strain was inoculated into wheat rice, and then at 30°C. Incubated for 6 days at 40°C for 1 day. The culture was made into a powder using a grinder.
해마다 바뀌는 소비 트렌드에 따라 곡물을 다양화한 발효 제품을 개발하기 위해 증자한 대두, 증자한 대두와 쌀, 증자한 대두와 소맥분, 증자한 소맥분에 상기 배양액 분말과 시중 판매되는 리조푸스 올리고스포러스 균주(Ragi Tempe Raprima, Bandung社, Indonesia)를 4% 접종 및 혼합한 다음, 습도를 60%로 조절하여 온도 30℃에서 1-2일간 배양하여 발효 제품인 템페를 만들었다.In order to develop fermented products with diversified grains according to the consumption trend that changes every year, the above-mentioned culture solution powder and the commercially available Rhizopus oligosporus strain are added to steamed soybean, steamed soybean and rice, steamed soybean and wheat flour, and steamed wheat flour. (Ragi Tempe Raprima, Bandung Corporation, Indonesia) was inoculated and mixed with 4%, and then the humidity was adjusted to 60% and cultured at 30° C. for 1-2 days to make tempe, a fermentation product.
배양한 템페들과 시중 판매되는 재래식 템페를 TSA(Tryptic soy agar)와 Polymyxin B 및 Trimethoprim을 첨가한 Bacillus cereus 선택 배지에 30℃ 1일간 배양하였다. 실시예 1에서 분리한 리조푸스 올리고스포러스 CJCC02-20균주를 접종한 템페들에서는 식중독 유발 세균인 바실러스 세레우스(Bacillus cereus)와 장관병원성 대장균(Escherichia coli)이 검출되지 않은 반면, 시중 판매되는 균주를 접종한 템페와 재래식 템페에서는 바실러스 세레우스(Bacillus cereus)가 검출됨을 확인하였다(표 2 참조). Cultured tempeh and commercially available conventional tempeh were cultured in Bacillus cereus selective medium supplemented with TSA (Tryptic soy agar), Polymyxin B and Trimethoprim for 1 day at 30°C. In the tempes inoculated with the Rhizopus oligosporus CJCC02-20 strain isolated in Example 1, Bacillus cereus and Escherichia coli, a food poisoning-inducing bacterium, were not detected, whereas the commercially available strains were not detected. It was confirmed that Bacillus cereus was detected in the inoculated tempeh and the conventional tempeh (see Table 2).
(unit/g)Protease activity
(unit/g)
* ND: Not Detected * ND: Not Detected
상기의 결과로서, 리조푸스 올리고스포러스 CJCC02-20균주는 템페 발효 균주로서 전통 풍미를 구현하면서 식중독 균을 제어할 수 있는 효과가 뛰어남을 확인하였다. As a result of the above, it was confirmed that the Rhizopus oligosporus CJCC02-20 strain is a tempeh fermented strain and has an excellent effect in controlling food poisoning bacteria while implementing traditional flavor.
따라서, 본 출원의 신규 리조푸스 올리고스포러스 CJCC02-20균주, 상기 균주의 포자, 상기 균주의 배양물, 그의 농축물 및 그의 건조물 등을 포함하는 항균조성물은 진균 및 식중독균에 대한 항균효과가 뛰어나므로 이를 포함하는 식품, 의약외품, 의약품 등에 효과적으로 사용될 수 있다. Therefore, the antibacterial composition comprising the novel Rhizopus oligosporus CJCC02-20 strain of the present application, the spores of the strain, the culture of the strain, its concentrate and its dried product, etc. has excellent antibacterial effect against fungi and food poisoning bacteria. It can be effectively used for food, quasi-drugs, and pharmaceuticals containing them.
이상의 설명으로부터, 본 출원이 속하는 기술분야의 당업자는 본 출원이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시 예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해해야만 한다. 본 출원의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 출원의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present application pertains will understand that the present application may be embodied in other specific forms without changing the technical spirit or essential characteristics thereof. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not restrictive. The scope of the present application should be construed as including all changes or modifications derived from the meaning and scope of the claims to be described later rather than the above detailed description and their equivalent concepts to be included in the scope of the present application.
<110> CJ CheilJedang Corporation <120> Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same <130> KPA201759-KR <160> 7 <170> KoPatentIn 3.0 <210> 1 <211> 1746 <212> RNA <213> Unknown <220> <223> Rhizopus oligosporus CJCC02-20 18s rRNA <400> 1 caagattaag ccatgcatgt ctaagtataa ataactttat attgtgaaac tgcgaatggc 60 tcattaaatc agttatgatc tacgtgacaa attctttact acttggataa ccgtggtaat 120 tctagagcta atacatgcaa aaaagccctg actcacgaag gggtgcactt attagataaa 180 accaacgcgg ggtaaaacct gtttcgtggt gaatcataat aattaagcgg atcgctggcc 240 ttgagccggc gacggtccac tcgattttct gccctatcat ggttgagatt gtaagataga 300 ggcttacaat gcctataacg ggtaacgggg aattagggtt cgattccgga gagggagcct 360 gagaaacggc taccacatcc aaggaaggca gcaggcgcgc aaattaccca atcccgacac 420 ggggaggtag tgacaataca taacaatgca gggcctttac ggtcttgcaa ttggaatgag 480 tacaatttaa tcccttaacg aggatcaatt ggagggcaag tctggtgcca gcagccgcgg 540 taattccagc tccaatagcg tatattaaag ttgttgcagt taaaacgtcc gtagtcaaac 600 tttagtctta ccggcgcggt ggcctggtct tcattgatca agctcgctgt cgctggagac 660 tccacgtccg ctggctccta gtcctcgtgg ctagggtttt gtggacaatt accatgagca 720 aatcagagtg tttaaagcag gctttaagct tgaatgtgtt agcatggaat aatgaaatat 780 gactttagtc ctattttcgt tggtttaggt actatagtaa tgattaatag aaacggttgg 840 gggcatttgt atttgcccgc tagaggtgaa attcttggat tggccgaaga caaactactg 900 cgaaagcatt tgacccagga cgttttcatt gatcaaggtc taaagttaag ggatcgaaga 960 cgattagata ccgtcgtagt cttaaccaca aactatgccg actagagatt gggcgtgttt 1020 cttttgactc gctcagcatc ttagcgaaag taaagttttt gggttctggg gggagtatgg 1080 gacgcaaggc tgaaacttaa aggaattgac ggaagggcac caccaggagt ggagcctgcg 1140 gcttaatttg actcaacacg gggaaactca ccaggtccag acatagtaag gattgacaga 1200 ttgaaagctc tttctagatt ctatgggtgg tggtgcatgg ccgttcttag ttcgtgagtg 1260 atttgtctgg ttaattccga taacgaacga gaccttattc tgctaattac acaggctaac 1320 tctttcgggt tggtttatgt ttatcattta actgtgttct tagagagact atctgcttga 1380 agcagaggga agttttaggc aataacaggt ctgtgatgcc cttagatgtt ctgggccgca 1440 cgcgcgctac actgatgaag tcagcgagtt ataaccttgg ccggaaggtc tgggtaaact 1500 tttgaaactc atcgtgctgg ggatagagca ttgtaattat tgctcttcaa cgaggaattc 1560 ctagtaagcg cgagtcatca gctcgcgttg attacgtccc tgccctttgt acacaccgcc 1620 cgtcgctact accgattgaa tggttatagt gagcatatgg gatccgcaga atttgactgg 1680 caacagtcat tttctgcaga gaactatggc aaactaggct atttagagga agtaaaagtc 1740 gtaaca 1746 <210> 2 <211> 1268 <212> DNA <213> Unknown <220> <223> Rhizopus oligosporus CJCC02-20 ABP1 gene <400> 2 agctgtagtg caatgttcaa gctaaaaata agtttgtgta tgtgctctgc aactgcatga 60 tattctagaa cgactgtgtt gcattttctt ttaattgatc tgtttgttgg tttctagaag 120 taatgcaaaa acggttgtac aaacatacaa aaggtcatat gacagatacg ccatcctaat 180 aagcgaaata gtgagcacct gcaagggcat tttaattaat aaagtgactt aatagcaatt 240 atggggcttt caagcttcca gggggtattt tgtttattgc ttaagaaaag tgctgtcctt 300 gtattcaaaa gtctatattt ttttgttata taaatataca catggatcac taaactattt 360 cttggaggta cagagaaaga gaggggaagg aagaacacga tccagcatca tggtcgctat 420 ggtgtcactt cgtcaacaga cgtcatttta gctcaccctt ctctcctttc tctttttctc 480 gcttgtcttc cttttttagt aatgttatac atttaagcgg tttatgtggt accttgccat 540 ttacataaat aaggaagctc aagattttgc aagatgctag ttctttctca aatgaagttg 600 atctacgttt tttgtttctt tactttgctc ttaattgcta ctcaacaagt gagtgctgca 660 tgtggtgctg aaggttcatg tcatggtttc ggaggcggag agttgtgtaa tgacagatgc 720 aaacgatgct ctggccctac tggaaaatac aaacggggag cctgttgtgg tactttgaaa 780 caagcttgct gctgctatta cagctaatta atgatgtgat gtgtttaact ttataaagca 840 gttgctttat aaaattgaaa attgaaaaat aaaaatgtct gtctccactc ctctgtcttc 900 ttgtttgggg ttttaattca tatgtagacg tgttacatgc tctaattatc aattacagca 960 aatgatcatc aagaggcagc agggtgtaat gaaaaacaca agtccaacac ttagagagct 1020 cattttttgc gtttttgcgc ctcaaatgaa atgcaataat ttcgttcaat caaagctttt 1080 tttggatttt aatatgtaca agattgtaca gccattatac tattacaatc aaataaagcc 1140 tatttctctt ttcttgtttc ttctatttaa gcatttccaa cattcaaaag caagttagag 1200 ccttcgccct taccactagg taaataagcc actttggagg tttgtgataa tgtctgtgca 1260 atatcctt 1268 <210> 3 <211> 2119 <212> DNA <213> Unknown <220> <223> Rhizopus oligosporus CJCC02-20 chi2 gene <400> 3 gcatgcgcat agtaaacaat gcttaaacca gatgacatac atacgtctat gaatgcaact 60 gattgatcat gaaatagccg cttctttgtt ttcgaatgat atccctacca tttcttcctt 120 tttatttcaa tgtaacatga gttttaatag gtaatatatt acttgatatt attacttgat 180 attacctatg accctaatct tattcattaa cgtgtaactt gagctgcaat gggaaaaaaa 240 aagataatga agacatggca acattagccc acgcatataa atactcactg gacatcctga 300 catcaaatca ttatctttac acttttcttt cccttattct tcaacatgct cactcgtact 360 ttccttggaa tggctatatc tgccttcttg gcatcaactg gtgttcaagc tgcttggtcc 420 tctcatggcc ctaatgtcat gtactactgg ggtcaaaatt ctgctggcgg atcaaataca 480 caagcatcct taggcactta ctgtgagtct ggccaagtcg atgccgtcct cctgtccttc 540 cttcacgtct ttaacgttgg tggtatccct gaaatcaatc tttctagcgc ctgtgctggt 600 acctattttc ccaatactca actacttagt tgtcctgctg ttggtgctgg taagtgttaa 660 accttttgtt gtcggggtct cttaacatct ctttcttgat agatatcaag aaatgtcaag 720 acaagggcgt caaggtcata ctctctcttg gtggtgctgc tggtgtctat ggtttcacaa 780 gcgatgccca aggacaacag ttcgcacaga cgatctggaa cctctttggt ggtggaaact 840 cagacacacg tccatttggt gatgctgtta ttgacggtgt cgatcttgac attgaaggtg 900 gctcatctac gggttatgtc gcctttgtga atgctcttcg tcaaaagttc tccagcaact 960 tccttattgg tgctgctcct caatgcccct tccctgacgc catcctcggc agtgtgttga 1020 actcggctag tttcgactac gtcaatgttc agttctataa caactattgc tctgctactg 1080 gttcctcctt caactttgac acctgggata actgggccaa gacgacgtca cctaacaaga 1140 acgtcaagat catgtttacg gttcctggct catctactgc tgcaggcagc ggctacgttc 1200 ccatgtctac tcttcaaact atagttcctt ctcttgcttc caagtactcc agctacggcg 1260 gtgtctcagt ctgggatgcc tctcaagcct ggaataacgg tggcttcaac tctcaactct 1320 actcgcttgt ccacagcggt ggctccactc ctcctcctcc ttcctcttct tcagctacca 1380 agacaacaac aaaaacgaca gcaacaagca ccaagacgac gactacgact gcccctactg 1440 ctaccagcac acctggcagt tgtcctgttg ccaatcagcc ttgctctact caaaatcaat 1500 atgcttgtac agccgatggc aagtacgctg tctgcgacca tggcaaatgg gttgcctcct 1560 cctgcccctc caacactgtc tgcattccta ctaccgatgg tgcctctatc tactgtggtt 1620 atgctactgg ctctggcagc acttgtcctt cagtcagcgc actcgaaatt acagctgctt 1680 ctctcggctc taagaatggc cccgtacctc gcccatacaa ggcttccaag gttgctgctc 1740 aactcgctgt tacttccact gacaagaata gctttgaagc tgttatcaat gctcgtcgca 1800 ccacgctcac tccctttgaa aaatctgtta ctatcgaatt cactacacct tccaacatca 1860 agtttaccga atctgatatg ggtcccgttc gtcaagtcgg caacaaggtt cgtattcaag 1920 ccaagaatga ttataacgaa tccatgactc tcgtcgtcaa agtcaagggt tccatcaatt 1980 caggcgtctt tgtggctccc agtacttctg cttggaactt taaataaata ttgtattaga 2040 taataataat aataaaaaaa gtgcaataac gttttattgt acgtattgaa gcagatttat 2100 gtgtattata ttattaaaa 2119 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> ABP1 gene reading pair forward primer <400> 4 gagaaagaac tagcatcttg c 21 <210> 5 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> ABP1 gene reading pair reverse primer <400> 5 catcattaat tagctg 16 <210> 6 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> chi2 gene reading pair forward primer <400> 6 caacatgctc actcgtactt tcc 23 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> chi2 gene reading pair reverse primer <400> 7 gagccacaaa gacgcctgaa t 21 <110> CJ CheilJedang Corporation <120> Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same <130> KPA201759-KR <160> 7 <170> KoPatentIn 3.0 <210> 1 <211> 1746 <212> RNA <213> Unknown <220> <223> Rhizopus oligosporus CJCC02-20 18s rRNA <400> 1 caagattaag ccatgcatgt ctaagtataa ataactttat attgtgaaac tgcgaatggc 60 tcattaaatc agttatgatc tacgtgacaa attctttact acttggataa ccgtggtaat 120 tctagagcta atacatgcaa aaaagccctg actcacgaag gggtgcactt attagataaa 180 accaacgcgg ggtaaaacct gtttcgtggt gaatcataat aattaagcgg atcgctggcc 240 ttgagccggc gacggtccac tcgattttct gccctatcat ggttgagatt gtaagataga 300 ggcttacaat gcctataacg ggtaacgggg aattagggtt cgattccgga gagggagcct 360 gagaaacggc taccacatcc aaggaaggca gcaggcgcgc aaattaccca atcccgacac 420 ggggaggtag tgacaataca taacaatgca gggcctttac ggtcttgcaa ttggaatgag 480 tacaatttaa tcccttaacg aggatcaatt ggagggcaag tctggtgcca gcagccgcgg 540 taattccagc tccaatagcg tatattaaag ttgttgcagt taaaacgtcc gtagtcaaac 600 tttagtctta ccggcgcggt ggcctggtct tcattgatca agctcgctgt cgctggagac 660 tccacgtccg ctggctccta gtcctcgtgg ctagggtttt gtggacaatt accatgagca 720 aatcagagtg tttaaagcag gctttaagct tgaatgtgtt agcatggaat aatgaaatat 780 gactttagtc ctattttcgt tggtttaggt actatagtaa tgattaatag aaacggttgg 840 gggcatttgt atttgcccgc tagaggtgaa attcttggat tggccgaaga caaactactg 900 cgaaagcatt tgacccagga cgttttcatt gatcaaggtc taaagttaag ggatcgaaga 960 cgattagata ccgtcgtagt cttaaccaca aactatgccg actagagatt gggcgtgttt 1020 cttttgactc gctcagcatc ttagcgaaag taaagttttt gggttctggg gggagtatgg 1080 gacgcaaggc tgaaacttaa aggaattgac ggaagggcac caccaggagt ggagcctgcg 1140 gcttaatttg actcaacacg gggaaactca ccaggtccag acatagtaag gattgacaga 1200 ttgaaagctc tttctagatt ctatgggtgg tggtgcatgg ccgttcttag ttcgtgagtg 1260 atttgtctgg ttaattccga taacgaacga gaccttattc tgctaattac acaggctaac 1320 tctttcgggt tggtttatgt ttatcattta actgtgttct tagagagact atctgcttga 1380 agcagaggga agttttaggc aataacaggt ctgtgatgcc cttagatgtt ctgggccgca 1440 cgcgcgctac actgatgaag tcagcgagtt ataaccttgg ccggaaggtc tgggtaaact 1500 tttgaaactc atcgtgctgg ggatagagca ttgtaattat tgctcttcaa cgaggaattc 1560 ctagtaagcg cgagtcatca gctcgcgttg attacgtccc tgccctttgt acacaccgcc 1620 cgtcgctact accgattgaa tggttatagt gagcatatgg gatccgcaga atttgactgg 1680 caacagtcat tttctgcaga gaactatggc aaactaggct atttagagga agtaaaagtc 1740 gtaaca 1746 <210> 2 <211> 1268 <212> DNA <213> Unknown <220> <223> Rhizopus oligosporus CJCC02-20 ABP1 gene <400> 2 agctgtagtg caatgttcaa gctaaaaata agtttgtgta tgtgctctgc aactgcatga 60 tattctagaa cgactgtgtt gcattttctt ttaattgatc tgtttgttgg tttctagaag 120 taatgcaaaa acggttgtac aaacatacaa aaggtcatat gacagatacg ccatcctaat 180 aagcgaaata gtgagcacct gcaagggcat tttaattaat aaagtgactt aatagcaatt 240 atggggcttt caagcttcca gggggtattt tgtttattgc ttaagaaaag tgctgtcctt 300 gtattcaaaa gtctatattt ttttgttata taaatataca catggatcac taaactattt 360 cttggaggta cagagaaaga gaggggaagg aagaacacga tccagcatca tggtcgctat 420 ggtgtcactt cgtcaacaga cgtcatttta gctcaccctt ctctcctttc tctttttctc 480 gcttgtcttc cttttttagt aatgttatac atttaagcgg tttatgtggt accttgccat 540 ttacataaat aaggaagctc aagattttgc aagatgctag ttctttctca aatgaagttg 600 atctacgttt tttgtttctt tactttgctc ttaattgcta ctcaacaagt gagtgctgca 660 tgtggtgctg aaggttcatg tcatggtttc ggaggcggag agttgtgtaa tgacagatgc 720 aaacgatgct ctggccctac tggaaaatac aaacggggag cctgttgtgg tactttgaaa 780 caagcttgct gctgctatta cagctaatta atgatgtgat gtgtttaact ttataaagca 840 gttgctttat aaaattgaaa attgaaaaat aaaaatgtct gtctccactc ctctgtcttc 900 ttgtttgggg ttttaattca tatgtagacg tgttacatgc tctaattatc aattacagca 960 aatgatcatc aagaggcagc agggtgtaat gaaaaacaca agtccaacac ttagagagct 1020 cattttttgc gtttttgcgc ctcaaatgaa atgcaataat ttcgttcaat caaagctttt 1080 tttggatttt aatatgtaca agattgtaca gccattatac tattacaatc aaataaagcc 1140 tatttctctt ttcttgtttc ttctatttaa gcatttccaa cattcaaaag caagttagag 1200 ccttcgccct taccactagg taaataagcc actttggagg tttgtgataa tgtctgtgca 1260 atatcctt 1268 <210> 3 <211> 2119 <212> DNA <213> Unknown <220> <223> Rhizopus oligosporus CJCC02-20 chi2 gene <400> 3 gcatgcgcat agtaaacaat gcttaaacca gatgacatac atacgtctat gaatgcaact 60 gattgatcat gaaatagccg cttctttgtt ttcgaatgat atccctacca tttcttcctt 120 tttatttcaa tgtaacatga gttttaatag gtaatatatt acttgatatt attacttgat 180 attacctatg accctaatct tattcattaa cgtgtaactt gagctgcaat gggaaaaaaa 240 aagataatga agacatggca acattagccc acgcatataa atactcactg gacatcctga 300 catcaaatca ttatctttac acttttcttt cccttattct tcaacatgct cactcgtact 360 ttccttggaa tggctatatc tgccttcttg gcatcaactg gtgttcaagc tgcttggtcc 420 tctcatggcc ctaatgtcat gtactactgg ggtcaaaatt ctgctggcgg atcaaataca 480 caagcatcct taggcactta ctgtgagtct ggccaagtcg atgccgtcct cctgtccttc 540 cttcacgtct ttaacgttgg tggtatccct gaaatcaatc tttctagcgc ctgtgctggt 600 acctattttc ccaatactca actacttagt tgtcctgctg ttggtgctgg taagtgttaa 660 accttttgtt gtcggggtct cttaacatct ctttcttgat agatatcaag aaatgtcaag 720 acaagggcgt caaggtcata ctctctcttg gtggtgctgc tggtgtctat ggtttcacaa 780 gcgatgccca aggacaacag ttcgcacaga cgatctggaa cctctttggt ggtggaaact 840 cagacacacg tccatttggt gatgctgtta ttgacggtgt cgatcttgac attgaaggtg 900 gctcatctac gggttatgtc gcctttgtga atgctcttcg tcaaaagttc tccagcaact 960 tccttattgg tgctgctcct caatgcccct tccctgacgc catcctcggc agtgtgttga 1020 actcggctag tttcgactac gtcaatgttc agttctataa caactattgc tctgctactg 1080 gttcctcctt caactttgac acctgggata actgggccaa gacgacgtca cctaacaaga 1140 acgtcaagat catgtttacg gttcctggct catctactgc tgcaggcagc ggctacgttc 1200 ccatgtctac tcttcaaact atagttcctt ctcttgcttc caagtactcc agctacggcg 1260 gtgtctcagt ctgggatgcc tctcaagcct ggaataacgg tggcttcaac tctcaactct 1320 actcgcttgt ccacagcggt ggctccactc ctcctcctcc ttcctcttct tcagctacca 1380 agacaacaac aaaaacgaca gcaacaagca ccaagacgac gactacgact gcccctactg 1440 ctaccagcac acctggcagt tgtcctgttg ccaatcagcc ttgctctact caaaatcaat 1500 atgcttgtac agccgatggc aagtacgctg tctgcgacca tggcaaatgg gttgcctcct 1560 cctgcccctc caacactgtc tgcattccta ctaccgatgg tgcctctatc tactgtggtt 1620 atgctactgg ctctggcagc acttgtcctt cagtcagcgc actcgaaatt acagctgctt 1680 ctctcggctc taagaatggc cccgtacctc gcccatacaa ggcttccaag gttgctgctc 1740 aactcgctgt tacttccact gacaagaata gctttgaagc tgttatcaat gctcgtcgca 1800 ccacgctcac tccctttgaa aaatctgtta ctatcgaatt cactacacct tccaacatca 1860 agtttaccga atctgatatg ggtcccgttc gtcaagtcgg caacaaggtt cgtattcaag 1920 ccaagaatga ttataacgaa tccatgactc tcgtcgtcaa agtcaagggt tccatcaatt 1980 caggcgtctt tgtggctccc agtacttctg cttggaactt taaataaata ttgtattaga 2040 taataataat aataaaaaaa gtgcaataac gttttattgt acgtattgaa gcagatttat 2100 gtgtattata ttattaaaa 2119 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> ABP1 gene reading pair forward primer <400> 4 gagaaagaac tagcatcttg c 21 <210> 5 <211> 16 <212> DNA <213> Artificial Sequence <220> <223> ABP1 gene reading pair reverse primer <400> 5 catcattaat tagctg 16 <210> 6 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> chi2 gene reading pair forward primer <400> 6 caacatgctc actcgtactt tcc 23 <210> 7 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> chi2 gene reading pair reverse primer <400> 7 gagccacaaa gacgcctgaa t 21
Claims (14)
상기 진균은 아스퍼질러스 (Aspergillus) 속이고, 상기 세균은 바실러스 세레우스(Bacillus cereus) 또는 대장균(Escherichia coli)인 것인, 균주.
Rhizopus oligosporus CJCC02-20 (Rhizopus oligosporus CJCC02-20) strain deposited with accession number KCCM12893P with antibacterial activity against fungi and bacteria,
The fungus is Aspergillus ( Aspergillus ) genus, the bacteria is Bacillus cereus ( Bacillus cereus ) or Escherichia coli ( Escherichia coli ) Will, the strain.
The strain of claim 1, wherein the fungus is Aspergillus oryzae , Aspergillus niger , or a combination thereof.
The strain according to claim 1, wherein the strain has a specific antibacterial activity against Aspergillus duck material, Aspergillus niger or E. coli.
[Claim 6] The Rhizopus oligosporus CJCC02-20 strain according to any one of claims 1, 3 and 5, the spores of the strain, the culture of the strain, a concentrate thereof, and a dried product thereof selected from the group consisting of An antibacterial composition comprising any one or more as an active ingredient.
A food composition comprising the antimicrobial composition according to claim 6 .
The food composition according to claim 8, wherein the food is tempeh or a sauce comprising tempeh.
A feed composition comprising the antimicrobial composition according to claim 6 .
A pharmaceutical composition for the prevention or treatment of microbial infections caused by fungi, bacteria, or a combination thereof, comprising the antimicrobial composition according to claim 6 .
The pharmaceutical composition of claim 11, wherein the microbial infectious disease is any one or more selected from the group consisting of food poisoning, diarrhea, vomiting, enteritis, gastroenteritis, constipation, abdominal pain and abdominal distension.
A health functional food composition for preventing or improving microbial infections caused by fungi, bacteria, or a combination thereof, comprising the antibacterial composition according to claim 6 .
A quasi-drug composition comprising the antimicrobial composition according to claim 6 .
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210009548A KR102315879B1 (en) | 2021-01-22 | 2021-01-22 | Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same |
PCT/KR2021/003829 WO2022158641A1 (en) | 2021-01-22 | 2021-03-29 | Novel rhizopus oligosporus strain, and antimicrobial composition comprising same |
CN202180091326.8A CN117015599A (en) | 2021-01-22 | 2021-03-29 | Novel rhizopus oligosporus strain and antimicrobial composition comprising same |
JP2023538692A JP2024500928A (en) | 2021-01-22 | 2021-03-29 | Novel Rhizopus oligosporus strain and antibacterial composition containing it |
US18/273,347 US20240117294A1 (en) | 2021-01-22 | 2021-03-29 | Novel rhizopus oligosporus strain and antimicrobial composition including the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210009548A KR102315879B1 (en) | 2021-01-22 | 2021-01-22 | Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102315879B1 true KR102315879B1 (en) | 2021-10-22 |
Family
ID=78275751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210009548A KR102315879B1 (en) | 2021-01-22 | 2021-01-22 | Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240117294A1 (en) |
JP (1) | JP2024500928A (en) |
KR (1) | KR102315879B1 (en) |
CN (1) | CN117015599A (en) |
WO (1) | WO2022158641A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023214841A1 (en) * | 2022-05-06 | 2023-11-09 | 씨제이제일제당 (주) | Method for preparing grain tempeh, grain tempeh prepared by said method, sauce comprising prepared grain tempeh, and method for preparing same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130061448A (en) * | 2011-12-01 | 2013-06-11 | 샘표식품 주식회사 | RHIZOPUS SP. CONTAINING ACTIVITY OF α-AMYLASES AND HIGH ACTIVITY OF GLUCOAMYLASES AND METHOD FOR CULTURING THEREOF |
-
2021
- 2021-01-22 KR KR1020210009548A patent/KR102315879B1/en active IP Right Grant
- 2021-03-29 CN CN202180091326.8A patent/CN117015599A/en active Pending
- 2021-03-29 US US18/273,347 patent/US20240117294A1/en active Pending
- 2021-03-29 WO PCT/KR2021/003829 patent/WO2022158641A1/en active Application Filing
- 2021-03-29 JP JP2023538692A patent/JP2024500928A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20130061448A (en) * | 2011-12-01 | 2013-06-11 | 샘표식품 주식회사 | RHIZOPUS SP. CONTAINING ACTIVITY OF α-AMYLASES AND HIGH ACTIVITY OF GLUCOAMYLASES AND METHOD FOR CULTURING THEREOF |
Non-Patent Citations (3)
Title |
---|
Lett Appl Microbiol, Vol.35, No.4, pp.311-315 * |
Microorganisms,제8권,9호,1330,1-12면 (2020.08.31.) 1부.* * |
한국환경농학회지,제29권,1호,86-91면 (2010) 1부.* * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023214841A1 (en) * | 2022-05-06 | 2023-11-09 | 씨제이제일제당 (주) | Method for preparing grain tempeh, grain tempeh prepared by said method, sauce comprising prepared grain tempeh, and method for preparing same |
Also Published As
Publication number | Publication date |
---|---|
CN117015599A (en) | 2023-11-07 |
WO2022158641A1 (en) | 2022-07-28 |
US20240117294A1 (en) | 2024-04-11 |
JP2024500928A (en) | 2024-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6672441B2 (en) | Novel Bacillus beresensis CJBV and antibacterial composition containing the same | |
KR102500894B1 (en) | Lactic acid bacteria and their uses | |
US9080219B2 (en) | Bacillus amyloliquefaciens K317 for suppressing the growth of antibiotics-resistant pathogenic microorganism or enteropathogenic microorganism | |
KR101761379B1 (en) | Novel Lactobacillus sakei K040706 for multi function and culture method thereof | |
KR102052056B1 (en) | Lactobacillus plantarum having antibacterial activity and uses thereof | |
KR101839374B1 (en) | Bacillus subtilis SCGB 574 strain having antimicrobial activity and probiotics properties and uses thereof | |
KR102052047B1 (en) | Pediococcus pentosaceus having antibacterial activity and uses thereof | |
KR101959730B1 (en) | Staphylococcus gallinarum strain with antibiotic activity and antibiotic use thereof | |
KR102044365B1 (en) | Bacillus subtilis SCDB 291 strain having improved mucosal adhesive capacity, gene synthesizing antimicrobial compound and probiotics properties and uses thereof | |
KR101865461B1 (en) | A antimicrobial peptide and a antimicrobial composition containing the same | |
KR102178350B1 (en) | Bacillus safensis strain with antibiotic activity and antibiotic use thereof | |
KR102315879B1 (en) | Novel Rhizopus oligosporus strain and antibacterial and antifungal composition comprising the same | |
KR102424598B1 (en) | Lactobacillus pentosus OKBL-L.PE 1 strain having antioxidant activity, anti-inflammatory activity, skin whitening activity, antimicrobial activity against pathogenic microorganism and anti-thrombotic activity and uses thereof | |
KR101715560B1 (en) | Novel Bacillus velezensis CJBV and antibacterial and antifungal composition comprising the same | |
KR101839372B1 (en) | Bacillus subtilis SCGB 634 strain having acid-resistance activity, bile acid-resistance activity, antioxidant activity and antimicrobial activity and not producing biogenic amine and secreting protease, cellulase and amylase and uses thereof | |
KR101839371B1 (en) | Bacillus amyloliquefaciens SRCM 100731 strain having antimicrobial activity and probiotics properties and uses thereof | |
KR102159379B1 (en) | Bacillus subtilis SRCM101371 strain having improved mucosal adhesive capacity and extracellular enzyme secretion activity and probiotics property and uses thereof | |
KR101627806B1 (en) | The culturing method for increasing immune-enhancing activity in Lactobacillus spp. | |
KR20080087230A (en) | Lactic acid bacteria separated from kimchi and uses thereof | |
KR101811238B1 (en) | Bacillus subtilis SCGB 159 strain having antioxidant activity, lipase inhibition activity and antimicrobial activity and not producing biogenic amine and secreting protease and amylase and uses thereof | |
KR101149819B1 (en) | Pharmaceutical compositions containing Sporolactobacillus vineae SL153 as an active ingredient with the ability of growth suppression of pathogenic microorganisms | |
KR20240112382A (en) | Novel Lactobacillus reuteri strain producing prebiotic alternan and uses thereof | |
KR20240055598A (en) | Novel strain of Bacillus velezensis and uses thereof | |
KR20240103082A (en) | Novel heat resistant spore forming strains and probiotics uses thereof | |
KR101811244B1 (en) | Bacillus subtilis SCGB 235 strain having antioxidant activity, lipase inhibition activity and antimicrobial activity and not producing biogenic amine and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GRNT | Written decision to grant |